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Mechanisms in the regulation of lipogenesis or lipolysis in adipose tissue significantly 
contribute to not only uncovering novel treatments for metabolic diseases in human health, but 
also creating economic profits to markets by improving livestock meat quality. This dissertation 
describes the investigation of lipid desaturation by ectopically expressed porcine stearoyl-
desaturase 1 (SCD1) in non-adipocytes and the extent of lipolysis mediated by various kinds of 
selective ß-adrenergic receptor (ß-AR) agonists ex vivo and in vitro.  
Inducible lentiviral expression vectors were generated for over-expression or knock-down 
of porcine SCD1 in the swine kidney 6 (SK6) cells. pSCD1-transduced SK6 cells successfully 
overexpressed pSCD1 expression as compared to uninduced SK6 (P < 0.05). pSCD1-transduced 
SK6 cells transfected with pSCD1shRNA significantly suppressed pSCD1 expression. 
Furthermore, the pSCD1-transduced cells incubated with 50 µM palmitic acid increased the 
synthesis of palmitoleic acid nearly 4-fold, indicating that the pSCD1-transduced cells successfully 
can induce the ∆9 desaturation of palmitic acid to palmitoleic acid. 
 ß-AR subtypes were characterized in bovine subcutaneous (s.c.) and intramuscular (i.m.) 
adipose tissues with the use of selective ß-,  ß- and ß-AR agonists. The most abundant ß-AR 
mRNA in both adipose tissues was the ß2-AR (P < 0.05). Isoproterenol, ractopamine, and zilpaterol 
stimulated the release of glycerol and nonesterified fatty acid (NEFA) from s.c. adipose tissue, but 
BRL-37344 did not affect lipolysis in s.c. adipose tissue in ex vivo cultures. A novel ß-agonist 
suppressed the stimulation of cAMP production mediated by ß1- and ß2-AR agonists in s.c. adipose 
tissue (P <0.05). In contrast, these ß-AR agonists were not effective in i.m. adipose tissue.   
 
 iii 
Finally, we investigated mechanisms regulating ß-AR stimulation mediated by 
dobutamine, salbutamol, and a novel ß-agonist in primary bovine s.c. and i.m. adipocytes. The 
stimulation of ß1-AR through dobutamine significantly activated adenylyl cyclase and protein 
kinase A, and concurrently increased glycerol release in s.c. adipocytes, more than salbutamol did 
(P < 0.05). The effects by ß-AR agonists were blocked by propranolol. A novel ß-agonist inhibited 
adenylyl cyclase and protein kinase A activation in s.c adipocytes (P < 0.05). In contrast, these ß-
AR agonists were not effective in i.m. adipocytes. In conclusion, this research has suggested the 
opportunity not only to develop a non-rodent biomedical model of obesity and metabolic disease 
but also to contribute to the understanding of functionality of ß-AR subtypes in adipose tissue 
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CHAPTER I  
INTRODUCTION  
Adipose tissue is the body’s largest repository of energy, and it plays an important role in 
total energy homeostasis. When energy production exceeds energy expenditure of the body, the 
remaining energy is stored as the form of triglycerides in adipose tissue (Krahmer et al., 2013). 
Hence, the excessive accumulation of adipose tissue can be a major risk factor triggering serious 
health problems such as obesity and obesity-related disorders.    
Dietary fat is one of the most important sources of nutrients for supporting our body and 
can be derived from animal fat and vegetable oils. However, the consumption of a fat-rich diet has 
been responsible for the growing problem of obesity. In fact, many studies have demonstrated that 
a high-fat diet can easily induce obesity in human and laboratory animals (Hill et al., 2000; 
Schrauwen and Westerterp, 2000; Ghibaudi et al., 2002; Jequier, 2002; Buettner et al., 2007). 
Some studies have also reported that fatty acid composition of the diets is a more important factor 
in diet-induced obesity rather than the amount of energy from fat (Bourgeois et al., 1983; DeLany 
et al., 2000; Wang et al., 2002; Kien et al., 2005) because saturated fatty acids (SFA) are more 
obesogenic than either monounsaturated fatty acids (MUFA) or polyunsaturated fatty acids 
(PUFA) (Takeuchi et al., 1995; Piers et al., 2003; Ailhaud et al., 2006; Silva et al., 2006). 
Stearoyl-CoA desaturase 1 (SCD1) is a central lipogenic enzyme and is highly responsible 
for the obesogenic effect derived from dietary SFA since SCD1 catalyzes biosynthesis of MUFA 
from SFA that is ether derived from the diet or synthesized de novo (Paton and Ntambi, 2009). 
MUFA, especially, palmitoleic (C16:1) and oleic (C18:1) acids are then used not only as major 
substrates for the synthesis of membrane phospholipids and triglycerides (Tocher et al., 1998; 
Miyazaki et al., 2001a), but also serve as mediators in signal transduction and cellular 
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differentiation (Bradley et al., 2008; Yonezawa et al., 2008). Thus, the abnormal alteration of ratio 
SFA to MUFA has been implicated in a key metabolic pathogenesis such as obesity, cardiovascular 
disease, and diabetes (Paton and Ntambi, 2009). These points of view have been supported by 
studies that showed Scd1 deficient mice have increased energy expenditure, reduced body 
adiposity, and are resistant to diet-induced obesity (Ntambi et al., 2002). Therefore, SCD1 could 
be an important metabolic control point, and the regulations of SCD1 expression and catalytic 
activity seem to expect an important point for the treatment of obesity and obesity-related disease.  
Epidemiological studies have reported a significant correlation between MUFA intake and 
a decrease in the risk factors for coronary heart disease (CHD) (Baggio et al., 1988; Grundy et al., 
1988; Kris-Etherton et al., 2002; Mente et al., 2009). Our laboratory has also demonstrated this 
effect in the studies through beef consumption enriched in either SFA and trans-fatty acids or 
enriched in oleic acid (Adams et al., 2010; Gilmore et al., 2011; Gilmore et al., 2013). Our studies 
have provided information that the major MUFA, oleic acid, from red meat can also be a good 
source as dietary fat for heart-healthfulness.  
As the amount of intramuscular (i.m.) lipid increases, total MUFA concentration is also 
elevated in the cattle (Smith et al., 2009). The formation of i.m. adipose tissue plays an important 
economic role in U.S., Japanese, Korean and Australia beef production as i.m. adipose tissue is 
considered an important index used to evaluate beef quality traits because of its contribution to 
organoleptic attributes such as juiciness, flavor, and tenderness (Savell and Cross, 1998). 
Control of lean and excessive subcutaneous (s.c.) adipose tissue deposition in livestock and 
meat industries is important, for it is directly linked to improvement of product quality, thereby 
leading to economic profits to providers, and satisfaction of consumers that desire a lean, reliable 
healthy product of consistent quality. Various strategies have been proposed to manipulate the fat 
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and muscle ratio for livestock production (Sillence, 2004). As one of the strategies, using synthetic 
ß-agonists (ß-AA) has been applied in livestock production for more than three decades due to its 
repartitioning effects. These ß-AA redirect nutrients away from adipose tissue and toward muscle 
disposition, which results in improvement of feed utilization, lean growth rate, and carcass lean 
percentage in cattle, pigs, poultry and sheep (Anderson et al., 2005). The mechanism of 
repartitioning effects includes both increase in muscle protein synthesis and decrease in their 
muscle protein degradation, and stimulation of triacylglycerol degradation and inhibition of fatty 
acid synthesis in adipose tissue (Emery et al., 1984; Jones et al., 1985; Moloney et al., 1990; 
Schiavetta et al., 1990; Smith et al., 1995). However, the precise mechanisms how the ß-AA 
control adipose tissue growth remains unclear. At present, most ß-AA commercially available, 
such as zilpaterol, ractopamine, cimaterol, terbutaline, matuberol and salbutamol, target ß1- and 
ß2-adrenergic receptors (ß-AR). The ß3-AA have limited application in livestock production.  
Elucidating aspects of lipogenesis or lipolysis mechanisms not fully understood in adipose 
tissue will make significant contributions to human health, not only suggesting therapeutic insights 
to uncover novel treatments for metabolic diseases in human, but also creating economic profits 
to markets by improving product quality. Therefore, we hypothesized that SCD1 ectopically 
modulated can effectively regulate lipid desaturation in the body. We also hypothesized that ß-AR 
subtypes would exhibit different responses in bovine s.c. and i.m.  adipose tissues. Taken together, 
the objective of this dissertation includes the following:  
- To generate lentiviral expression vectors to overexpression or knock-down of   
    porcine SCD1 in the porcine kidney cells as a preliminary study to develop  
    porcine biomedical models for obesity-associated disorders and pork products  
    with healthy characteristics. 
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-  To characterize ß-AR subtypes in bovine s.c. and i.m.  adipose tissues with the  
 use of selective ß-AR agonists and antagonists, including a novel -agonist  
 ExperiorTM.    
-  To investigate mechanisms regulating ß-AR stimulation mediated by selective  





CHAPTER II  
LITERATURE REVIEW 
 
Structure and physiology of adipose tissue 
 
The adipose tissue in mammals consists of one-third adipocytes and two-thirds a 
combination of small blood vessels, nerve tissue, fibroblasts and preadipocytes, referring to as the 
stromovascular fraction (Geloen et al., 1989). Adipocytes have two functionally different types of 
fat cells, white and brown. The brown adipose tissue (BAT) has polygonal, multiple small-
scattered lipid droplets with variable diameters, central nuclei, and a large number of mitochondria. 
The BAT is specialized in the dissipation of energy through cold and diet induced thermogenesis 
via mitochondrial uncoupling protein 1 (UCP1) (Hassan et al., 2012; Saely et al., 2012). Therefore, 
it is abundant in neonates and hibernating animals due to their inability to shiver. In contrast, white 
adipose tissue (WAT) is diametrically opposed to physiological function of BAT. It functions as 
the central repository of energy storage and secretion of hormones and cytokines that regulate body 
metabolism. Unlike BAT, WAT has spherical, single lipid droplet with a larger diameter (100 µm 
or more), peripheral nuclei, and variable amounts of mitochondria. In mammals, the WAT is 
mainly located beneath the skin (subcutaneous fat), around the kidney (perinephric fat), gonads 
(inguinal/gonadal fat), GI track (omental/mesenteric fat), between muscle (intermuscular fat), and 
within muscles (intramuscular fat) (Mersmann and Smith, 2005; Saely et al., 2012).  
Adipose tissue mass is determined by hyperplasia (cell proliferation) and hypertrophy (cell 
enlargement) through lipid filing. Adipocyte number and size differ from adipose depot regions. 
In cattle, subcutaneous (s.c.) adipose tissue hyperplasia is complete about 8 mo of age, but 
intramuscular (i.m.) adipose tissue hyperplasia is process at 14 mo of age, indicating that i.m. is a 
late developing depot. Further increase in both adipose tissue mass is progressed by hypertrophy 
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(Hood and Allen, 1973). Furthermore, s.c. adipocyte diameter increased before 13 mo of age, 
whereas, i.m. adipocyte diameter increased before 15 mo of age. The average adipocyte diameter 
unchanged after 17 mo of age, suggesting that adipocyte hypertrophy increased until 17 mo of age 
in cattle (Cianzio et al., 1985).  
 
Adipogenesis 
Adipogenesis defines as the overall process of preadipocyte determination, growth, and 
terminal differentiation. Preadipocyte differentiation begins in late prenatal and early postnatal 
development in different anatomical sites (Spiegelman et al., 1993). The adipocyte lineage is 
derived from multipotent mesenchymal stem cells (MSC) by sequential differentiation pathways. 
The MSCs are programmed to become committed adipocyte lineage when appropriate differential 
signals are triggered. This process, known as determination, results in the conversion of the MSCs 
to preadipocytes, but has lost the capacity to differentiate into other cell types. Although there have 
been lots of efforts to define distinct intermediate steps in determination of primitive MSCs to the 
adipocyte lineage, it is still unknown what early molecular factors are really involved (Gesta et al., 
2006). 
 Preadipocytes have a fibroblast-like morphology, and express surface markers such as 
preadipocyte factor 1(Pref-1), adipose tissue specific secretory factor (ADSF), alpha 2 chain of 
type VI collagen (COL6A2) and secreted frizzled related protein 2 (SFRP2). The SFRP2 is 
particularly plentiful in subcutaneous fat (Gesta et al., 2006). All preadipocyte markers are highly 
expressed in preadipocytes, and markedly reduced in mature adipocytes, indicating that they 
enable to control fat cell differentiation and adipose tissue development (Ibrahimi et al., 1993; Hu 
et al., 1998; Villena et al., 2002). 
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Preadipocytes undergo the terminal differentiation, that is, preadipocytes turn into mature 
adipocytes. This process involves four distinct states: growth arrest, clonal expansion, early 
differentiation, and terminal differentiation. It has been extensively studied in mouse 3T3-L1 and 
3T3-F442A cell lines and immortalized brown adipocytes (Rosen and Spiegelman, 2000; Rosen 
and MacDougald, 2006). The first stage in the differentiation of preadipocytes starts from growth 
arrest. In cultured cell model, initial growth arrest is induced by the addition of a prodifferentiative 
hormonal agent and undergoes at least one round of DNA replication and cell division known as 
clonal expansion. In very early stage of differentiation, c-fos, c-jin, junB, c-myc are expressed 
(Cornelius et al., 1994). C-myc has been shown to initiate mitogenesis in the process of 
differentiation in preadipocytes, suggesting that c-myc may act as branch point at which the growth 
arrested cells face either directly cell cycle reentry or terminal differentiation (Ntambi and Young-
Cheul, 2000).  
After clonal expansion, preadipocytes undergo a second and final period of growth arrest 
to reach terminal differentiation into mature adipose phenotype. Preadipocyte early and terminal 
differentiation is controlled by the sequential expression of key transcription factors, including the 
CCAAT/enhance binding protein (C/EBP), the peroxisome proliferator-activated receptor (PPAR) 
families, and the adipocyte determination and differentiation factor-1/sterol response element 
binding protein 1c (ADD1/SPEBP1c) (Ailhaud et al., 1992; Mandrup and Lane, 1997; Rosen et 
al., 2000). C/EBP and C/EBP are the first transcription factors, which are control of exogenous 
promoters of induction of differentiation and accumulation of terminal transcription factors of 
adipogenesis, PPAR and C/EBP (Wu et al., 1995; Clarke et al., 1997; Lane et al., 1999).  
Terminal differentiation is accompanied by dramatic increase in the expression of C/EBP 
PPAR, glycerophosphate dehydrogenase (GPDH), fatty acid synthase (FAS), acetyl CoA 
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carboxylase (ACC), malic enzyme (ME), fatty acid binding protein (FABP) (Spiegelman et al., 
1993), which is followed by de novo or enhanced expression of the genes that specialize the 




Lipid droplets (or vacuoles) are ubiquitous, dynamic cellular lipid-storage organelles, 
function as lipid reservoirs for energy production, membrane synthesis, viral replication, and 
protein degradation. Lipid droplets consist of a nonpolar, neutral lipid core (i.e., triglyceride (TAG) 
and sterol esters) coated with a protein-bounded phospholipid monolayer, composing primarily of 
phosphatidylcholine, with lesser amounts of phosphatidylethanolamine, phosphatidylinositol, and 
lyso-phosphatidylcholine. Lipid droplet sizes vary dramatically from < 1 µm in diameter in 
fibroblasts to > 100 µm in white adipocytes (Tauchi-Sato et al., 2002; Walther and Farese, 2012).  
Lipid droplet formation could trigger either de novo TAG synthesis in the endometrial 
reticulum (ER) or the fusion of smaller lipoproteins. Several models of lipid droplet formation 
have been proposed such as ER budding, bicelle formation, vesicular budding and eggcup. Despite 
these models for explaining how to form lipid droplets, the molecular mechanisms of lipid droplet 
formation remain unclear.   
Wilfling et al. (2014) recently proposed a step wise model of lipid droplet formation: 1) neutral 
lipid synthesis; 2) lens formation (intramembrane lipid accumulation); and 3) lipid drop formation. 
Neutral lipid synthesis is mediated by enzymes of the membrane-bound O-acyltransferase 
(MBOAT) family (i. e., acyl CoA:cholesterol acyltransferase (ACAT1), ACAT2, and acyl-CoA: 
acyltransferase (DGAT1)) and DGAT2 gene families, generally localized to the ER. Specifically, 
TAG are formed with diacylglycerol and fatty acyl-CoA produced by acyl-CoA synthetase 
 
 9 
(ACSL) via DGAT between leaflets of the ER bilayer. When neutral lipid accumulation reaches a 
crucial threshold, lipid lenses may form in the ER as the oil phase coalesces. Once lipid droplets 
achieve a certain size, the bilayer detaches and a nascent lipid droplet buds into the cytoplasm 
(Wilfling et al., 2014). Further, the growth of lipid droplets involves the local synthesis of TAG at 
the surface of lipid droplets. In an excess environments of fatty acids, the volume of lipid droplets 
rapidly expand their volumes, and several proteins are involved to regulate lipid droplet size and 
number, such as the PAT family proteins (i.e., perilipin1, perilipin2/adipophilin (ADRP), 
perilipin3/Tip47, perilipin4/S3-12) CIDE (Cell Death Including DNA Fragmentation factor) 




Fatty acids (FA) are the major components of TAG, phospholipid, cholesterol esters, and 
wax esters. Fatty acids are comprised of a hydrogen carbon and a terminal carboxyl group, which 
is either saturated or unsaturated. Saturated fatty acids (SFA) do not have double bonds in the 
hydrocarbon chain whereas unsaturated fatty acids contain at least one double bond. The double 
bonds of unsaturated fatty acids have two distinct configurations, cis or trans, and are divided two 
subclasses: monounsaturated fatty acids (MUFA) with a single double bond and polyunsaturated 
fatty acids (PUFA) with two or more double bonds. Furthermore, based on chain length, they are 
categorized as short-chain, medium-chain, long-chain, or very-long-chain fatty acids: Short-chain 
(< C6); medium-chain (C6-C12); long-chain (C13-C22); and very-long chain (> C24) (Wang et al., 
2013). In animals, the number of carbon atoms in fatty acids is typically between C14 and C24, with 






Fatty acid biosynthesis 
Lipogenesis is a physiological process of endogenous fatty acid synthesis (de novo), and 
subsequent TAG synthesis. It mainly takes place both liver and adipose tissue but varies among 
the spices. In rat, both liver and adipose tissue are the major lipogenic organs; the liver dominates 
in chickens, fish, and humans; and, adipose tissue is the primary site in ruminants and pigs (Vernon 
et al., 1999). Additionally, in ruminants, most dietary carbohydrate is fermented to acetate, 
propionate, and butyrate in the rumen. Thus, acetate is used as the primary precursor for de novo 
fatty acid synthesis in adipose tissue (Vernon, 1980).   
The precursors of de novo fatty acid synthesis are derived from catabolism of carbohydrates 
and their metabolites (i. e., glucose, lactate, acetate, and pyruvate), and to a lesser extent, amino 
acids. Cytosolic acetyl-CoA and reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
are substrates for de novo synthesis. As lipogenesis takes place in the cytosol, mitochondrial 
acetyl-CoA itself is not directly used for de novo synthesis the mitochondrial membrane is not a 
permeable to acetyl-CoA. Instead, citrate, which is a condensation product of acetyl-CoA and 
oxaloacetate in the tricarboxylic acid (TCA) cycle, is transported to the cytosol, where it is cleaved 
into oxaloacetate and acetyl-CoA by the enzyme ATP-citrate lyase (Smith and Prior, 1981; 
Mersmann and Smith, 2005). NADPH is synthesized through pentose phosphate pathway, and 
NADP-malate dehydrogenase, and NADP-isocitrate dehydrogenase in ruminants (Smith, 1983) 
and via the pentose phosphate pathway and NADP-malate dehydrogenase in non-ruminants 
(Shingfield et al., 2010).  
De novo fatty acid synthesis is initiated by the carboxylation of acetyl-CoA to form 
malonyl-CoA via ACC. Next, another acetyl-CoA is condensed with malonyl-CoA by the FAS 
complex through multiple serial enzyme reactions, resulting in the synthesis of long-chain fatty 
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acids. The major end product of de novo synthesis is palmitic acid (C16:0). The palmitic acid has 
two fates: elongation by adding two-carbon moieties in a chain-elongation reaction, yielding 
stearic acid (C18:0) and desaturation via stearoyl-CoA desaturase. 
Insulin is considered as one of the important hormones for the regulation of fatty acid 
biosynthesis, as it activates enzymes such as acetyl-CoA carboxylase, ATP-citrate layase, and the 
pyruvate dehydrogenase complex (Potapova et al., 2000; Holness and Sugden, 2003; Brownsey et 
al., 2006).  
 
Stearoyl-coenzyme A desaturase 
 
Stearoyl-CoA desaturase (SCD) is a key enzyme in the biosynthesis of MUFA from SFA 
that are either synthesized de novo or derived from the diet. SCD catalyzes the Δ9-cis desaturation 
of fatty acyl-CoA substrates. SCD is bound to the ER and contains four membrane-spanning 
domains with the NH2 and COOH termini facing the cytoplasm. The SCD reaction is an aerobic 
process and involves a three-component enzyme system comprised of 11lavoprotein-NADH-
dependent cytochrome b5 reductase, cytochrome b5, and SCD (Heinemann and Ozols, 2003; Man 
et al., 2006; Paton and Ntambi, 2009). 
The SCD genes are ubiquitously expressed in higher organisms and have a high degree of 
variability in the gene complements of SCD in vertebrate species (Hodson and Fielding, 2013). 
Four isoforms (Scd1-Scd4) are present in the mouse, of which Scd1 is the best documented isoform 
(Sampath and Ntambi, 2006); whereas only two isoforms (SCD1 and SCD5) have been identified 
in humans, pigs, sheep, cattle, and chickens (Lengi and Corl, 2008). In mice, the Scd1 is expressed 
in the liver, brown and white adipose tissue, and sebaceous glands (Ntambi, 1999; Heinemann and 
Ozols, 2003; Miyazaki et al., 2005). Scd2 is universally expressed in most tissue except for liver 
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(Tabor et al., 1998), Scd3 is only expressed in the skin, and Scd4 is expressed solely in the heart 
(Zheng et al., 2001; Miyazaki et al., 2003). In humans and livestock species, SCD1 is expressed in 
adipose tissue, liver, muscle, lung, heart, intestine, and mammalian gland, although expression in 
the liver is lower than the mouse (Cameron et al., 1994; Wang et al., 2006; Lengi and Corl, 2008; 
Rezamand et al., 2014). SCD5 is mostly expressed in the brain and pancreas in humans, cattle, 
pigs, sheep, and chickens (Wang et al., 2005; Lengi and Corl, 2008).  
Ntambi and his colleges, forefront in the study of SCD, have created the Scd1 global and 
various tissue-specific knockout murine models for investigating the role of SCD1 for over two 
decades. The Scd1 global knockout model (SCD1-/-) was generated by Miyazaki et al in 2001 using 
C37BL/6 or SV129 mice (Miyazaki et al., 2001b). The Scd1 global knockout model is similar 
growth to wild-type mice on a chow diet, but they are leaner, accumulating less adipose tissue, 
although they consume 25% more food than wild type mice (Ntambi et al., 2002). In addition, the 
Scd1 global knockout mice had elevated levels of plasma ketones and greater insulin sensitivity 
but reduced levels of plasma insulin and leptin compared with the wild-type mice (Ntambi et al., 
2002). Moreover, the Scd1 global knockout had very low levels of TAG in the VLDL and low-
density lipoprotein (LDL) fractions compared to wild-type mice (Attie et al., 2002). Liver-specific 
Scd1 knockout mice were generated by Miyazaki et al. in 2007 using Cre-lox technology 
(Miyazaki et al., 2007). Liver-specific Scd1 knockout mice have the tolerance to high-carbohydrate 
diet, but not high-fat diet, which induced obesity and liver steatosis. Additionally, this model 
triggered a marked decrease in lipogenesis and a severe impairment of gluconeogenesis, leading 
to hyperglycemia and a reduction of liver carbohydrate (Miyazaki et al., 2007). Adipose tissue-
specific Scd1 knockout mice were generated by Hyun et al. in 2010 using Cre-lox technology 
(Hyun et al., 2010). The adipose tissue-specific Scd1 knockout mice displayed an increase in 
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GLUT1 and TFN- expression but a decrease in adiponectin expression (Hyun et al., 2010). 
Combined liver and adipose tissue-specific Scd1 knockout mice (Flowers et al., 2012) showed a 
robust reduction in SCDl MUFA products in both s.c. and WAT but were not protected from either 
genetic obesity or diet-induced obesity.      
SCD gene expression is highly regulated by dietary lipids (PUFAs, cholesterol, and vitamin 
A), hormonal factors, developmental processes, temperature, metals, alcohol, and peroxisomal 
proliferation (Ntambi, 1999). The predominant products of SCD are palmitoleoyl-and oleaoyl-
CoA (Ntambi, 1999). Palmitoleic and oleic acid serve as the major constituents of membrane 
phospholipids and TAG, cholesterol ester (CE), and wax ester found in fat depots (Miyazaki et al., 
2000; Miyazaki et al., 2001a; Miyazaki et al., 2001b). The ratio of stearic to oleic acids directly 
influences cell membrane fluidity, cell-cell interaction, signal transduction, and cellular 
differentiation (Kates et al., 1984; Gyorfy et al., 1997). An increasing SCD activity and, thereby, 
abnormal alteration between the ratio of stearic to oleic acids results in physiological and disease 
states such as aging, diabetes, obesity, heart disease and cancer (Ntambi, 1999). Therefore, the 
regulation of the SCD gene expression is an important for human health (Spector and Yorek, 1985; 




The adrenergic receptors (AR) belong to the G-protein-coupled receptors (GPCR), and 
have been divided into two major isoforms,  and ß. To date, seven -AR subtypes (1A, 1B, 
1D, 2A, 2B, 2C, and 2D) and three ß-AR subtypes (ß1, ß2, and ß3) have been identified in 
various tissues in the body, with the ß-AR subtypes predominating in cardiac, airway smooth 
muscle and adipose tissue (Woodcock, 2007; Lynch and Ryall, 2008).  
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The bovine ß1-, ß2-, and ß3-AR genes are located on chromosome 26, 7, and 27, 
respectively. The ß1- and ß2-AR genes encode an intronless gene transcript, whereas the 3-AR 
gene encodes a transcript containing a single intron. The bovine ß-AR consist of 405-467 amino 
acid residues with a protein molecular weight ranging from 42.9 to 50.1 kDa (Table 1). There is a 
64 to 69% homology between ß3-, ß2, and ß1-AR. Like all GPCR, the ß-AR have seven 
transmembrane-spanning -helices, which are connected with three extracellular loops with an 
amino-terminus and with three intracellular loops with a carboxy-terminus (Liggett, 2002). The 
sequences of seven transmembrane-spanning -helices are highly conserved between the ß-AR 
and have amino acid residues for either agonist- or antagonist-induced receptor trafficking. The 
third intracellular loop of the ß-AR has specific domains for central roles for G-protein coupling, 
desensitization, and downregulation  (Liggett, 2002; Johnson, 2006). 
  ß-AR oscillate between inactivated and activated states, and these two states are in 
equilibrium under resting conditions. The predominant state is the inactivated state (Liggett, 2002).  
The activation of the ß-AR is initiated when ligands such as hormones or neurotransmitters bind 
to agonist binding sites within transmembrane-spanning -helices. Ligand binding induces a 
conformational change in the ß-AR that leads to coupling with G-proteins that consist of , ß, and 
 subunits bound to the intracellular plasma membrane. Based on their amino acid sequences and 
function, G subunits are divided into four subfamilies, Gs, GI, Gq and G12. Upon the binding 
of a ligand to ß-AR, G subunits release G-protein-bound guanosine diphosphate (GPD), and 
subsequently bind to guanosine triphosphate (GTP). This activates the G subunits and dissociates 
it from Gß  subunits (Liggett, 2002). ß-AR predominantly couple with Gs and GI subunits 
(Wenzel-Seifert and Seifert, 2000). The ß-AR solely couples with Gs subunits, whereas the ß-
AR has dual coupling with both Gs and GI subunits (Xiao, 2001), which activates downstream 
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signaling pathways including adenylyl cyclase (AC), phosphoinositide 3-kinase/Ser and Thr 
kinase (PI3K/Akt), protein kinase A (PKA), ion-channel, extracellular-signal-regulated kinase 
(ERK), exchange protein activated by cAMP (Epac), and cyclic nucleotide-gated (CNG) signaling 
pathways (de Rooij et al., 1998; Murga et al., 1998; Dascal, 2001; Tasken and Aandahl, 2004; 
Craven and Zagotta, 2006; Robidoux et al., 2006). G subunits bound to GTP drastically reduces 
the affinity of ß-AR for their ligands, which causes dissociation of G subunits into the ß-AR and 
induces ß-AR to return to their inactive state (Johnson, 2006).  
Continuous, short-term stimulation of agonists to ß-AR triggers a rapid attenuation of 
receptor responsiveness, known as desensitization. This mechanism includes three main processes: 
1) uncoupling of the receptors from G-proteins in response to receptor phosphorylation; 2) 
internalization of uncoupled receptors; and 3) phosphorylation of internalized receptors (Ferguson, 
2001; Johnson, 2006). The degree and duration of the ß-AR/agonists responses have various 
influences on the extent of desensitization. There are two principal mechanisms of desensitization, 
homologous and heterologous. Homologous desensitization is initiated when the Gß subunits of 
the activated G-protein bind with an activated G-protein-coupled receptor kinase (GRK). GRK 
selectively phosphorylates the C-terminus of the agonist-bound ß-AR, thereby recruiting and 
binding cytosolic cofactor proteins called ß-arrestins to ß-AR and resulting in dissociation of the 
receptors from G-proteins. This leads to limiting receptor functions. In contrast, heterologous 
desensitization begins when second messenger-dependent PKA phosphorylates not only the 
agonist-bound ß-AR but also agonist-unbound ß-AR (Madamanchi, 2007). ß-AR phosphorylation 
recruits ß-arrestins, and ß-arrestins interfere with further binding of G-proteins to receptors, 
ultimately releasing G-proteins from receptors. At more prolonged agonist exposure, some 
receptors are sequestered from the cell surface, termed sequestration, which leads to occurrence of 
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receptor internalization. Following internalization, receptors are transported to endosomes where 
the receptors are recycled back to the plasma membrane to receive new signals. In response to 
chronic agonist over-exposure, down-regulation of the cellular receptors occurs. This process 
reduces not only ß-AR mRNA and protein synthesis but degrades also pre-existing receptors in 
the liposome and plasma membrane. The time frames over which these processes take place are 
from seconds (phosphorylation) to minutes (endocytosis) and hours (down-regulation) (Ferguson, 
2001; Johnson, 2006; Madamanchi, 2007).      
                 
Table 1. Structural characteristics of the ß-Adrenergic receptors 
Subtypes Location Transcript length (bp) Translation length Mr, Da 
1 Chromosome 26 1404 467 50,137 
 Chromosome 7 1257 418 47,136 
 Chromosome 27 1959 405 42,903 
 
 
ß-Adrenergic receptor agonists and antagonists 
 
Agents such as drugs, hormones, or neurotransmitters that interact with ß-AR can be 
classified as agonists or antagonists based on their actions to ß-AR. Agonists are compounds that 
stimulate ß-AR to induce the chemical and physiological changes by only modulating functions or 
processes already existent without de novo effects. In contrast, antagonists bind specifically to the 
same receptor sites where agonists bind and block the ability of agonists to occupy and activate 
that receptor, thereby inactivating intracellular signaling pathways (Hershberger, 1994). There are 
two general types of antagonists, competitive and noncompetitive. Competitive antagonists trigger 
agonist dissociation by increasing concentration of agonist, whereas noncompetitive antagonists 
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do not allow receptors to be activated by agonists despite extremely high agonist concentrations 
because of their irreversible binding to receptors (Hershberger, 1994).  
ß-agonists have an asymmetric center with aromatic group, hydroxyl group linked to the 
ß-carbon, and aliphatic nitrogen (Smith, 1998). Due to the presence of an asymmetric center, ß-
agonists form a pair of optical isomers, the R- and S-enantiomers (or [-] and [+]). Some agonists, 
such as fentoterol, formoterol, and ractopamine, have two asymmetric centers, and there are four 
enantiomers, RR, SS, RS, and SR, present (Mills et al., 2003; Johnson, 2006). The molecular 
structure of ß-agonists is crucial for determining the way in which they interact with the ß-AR. 
Short-acting ß-agonists (e.g., salbutamol) are hydrophilic in nature, so they are able to access the 
active site of the ß-AR directly from the extracellular aqueous compartment, thereby provoking a 
rapid onset of action. However, as short-acting ß-agonists rapidly re-equilibrate, their duration at 
the receptor active site is short (4-6 h) (Johnson, 2001, 2006). In contrast, long-acting ß-agonists 
such as fermoterol and salmeterol are lipophilic in nature, and they are absorbed into the cell 
membrane in the form of a depot. The size of the depot depends on the concentration of long-
acting ß-agonists. Therefore, the onset of action of these ß-agonists is slower than that of short-
acting ß-agonists, but the duration of action is longer and concentration-dependent (Johnson, 2001, 
2006).   
  ß-AR waver between inactivated and activated states, and these two states are in 
equilibrium under resting conditions. The inactivated state is dominant (Liggett, 2002). ß-agonists 
bind to the ß-AR and shifts the equilibrium to the active state. ß-agonists interchangeably behave 
as full or partial agonists in compliance with their potencies and receptor densities. When ß-
agonists completely shift the equilibrium in the direction of active state of receptor, they are called 
full agonists. In contrast, ß-agonists that promote an intermediate state of receptor activation vs 
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inactivation are called partial agonists (Hershberger, 1994). For these reasons, full ß-agonists have 
a high efficacy (Emax), the maximum response reachable from a dosed agent; partial ß-agonists 
have an intermediate efficacy; and pure ß-antagonists have low or zero efficacy (Johnson, 2006). 
Most ß2-agonists have an intermediate efficacy. If enough densities of ß-AR are present, then, ß2-
agonists behave as full agonists. However, receptor densities are too low, or receptor couplings are 
inadequate, they behave as partial agonists. Therefore, a partial agonist requires a higher 
occupation of receptors than a full agonist to reach its maximum effect (Johnson, 2006).  
ß-agonists have been used for the treatment of chronic bronchitis, chronic obstructive 
pulmonary disease, asthma, uterine relaxants, and cardiac irregularities for more than 30 years 
(Barnes, 1999).  Interestingly, some ß-agonists have identified “repartitioning effects”, inducing 
increase in skeletal muscle mass and decrease in body fat (Emery et al., 1984). As a consequence 
of repartitioning effects, many studies on revealing the effects of ß-agonists have been conducted 
in human medicine and livestock industry with the aim of discovering new pharmaceuticals for 
muscle wasting disorders (Carter et al., 1991; Maltin et al., 1993; Kissel et al., 1998; Lynch et 
al., 2001), and of improving feed efficiency and meat quality (Hamby et al., 1986; Hoey et al., 
1995; Bell et al., 1998; Mersmann, 1998).  
   In the livestock industry, many studies demonstrate that the oral administration of ß-
agonists (e.g., clenbuterol, cimaterol, ractopamine, and zilpaterol) with high doses and/or 
extended days in cattle, pigs, chickens, and sheep resulted in a muscle hypertrophic response due 
to the increase in muscle protein synthesis (Smith et al., 1995) and reduction of their muscle 
protein degradation. Furthermore, they concomitantly reduce the adipose tissue mass due to the 
stimulation of TAG degradation and inhibition of fatty acid synthesis (Baker et al., 1984; 
Dalrymple et al., 1984; Ricks et al., 1984; Jones et al., 1985; Moser et al., 1986; Beermann et al., 
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1987; Coleman et al., 1988; Miller et al., 1988; Schiavetta et al., 1990; Mersmann, 2002; Allen et 
al., 2009; Elam et al., 2009). In addition, some studies also demonstrate that certain ß-agonists 
such as clenbuterol and cimaterol increase the peripheral blood flow and influence the release of 
insulin, growth hormone, thyroid hormones, and corticosteroids (Bassett, 1970; Beermann et al., 
1986; Beermann et al., 1987). For instance, clenbuterol upregulates the concentration of glucose, 
insulin, and free fatty acids in calves and increases activity of specific liver enzyme alanine 
aminotransferase and alkaline phosphatase in pigs (Luthman and Jacobsson, 1993; Gojmerac et 
al., 2002). The mechanism regulating tissue responsiveness to ß-agonists differs from species to 
species and even tissues within a species because of variations of each receptor subtype in 




In response to cellular signal cascades caused by ß-agonists in adipocytes, lipid droplets 
are subjected to lipolysis to release mobilized fatty acids and other metabolites derived from stored 
neutral lipids, which are used for energy generation, membrane biogenesis, protein modification, 
and secretion within lipoproteins (Barbosa et al., 2015). These processes are highly regulated by 
specific enzymes and hormones. In adipocytes, lipolysis of TAG in lipid droplets is initiated by 
the binding of ß-agonists such as epinephrine and isoproterenol to their receptors, which are 
coupled to stimulatory G protein Gs, and in turn, interacts with the membrane-bound AC to 
catalyze the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP), the “intracellular second messenger”. The increased concentration of cAMP results in 
activation of PKA by binding to the PKA regulatory subunits. PKA phosphorylates perilipin and 
hormone-sensitive lipase (HSL), and phosphorylated perilipin undergoes a conformational change, 
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allowing HSL to gain access to stored lipid. Adipose tissue TAG lipase first cleaves the sn-1 fatty 
acyl group from the TAG. Then, HSL acts on diacylglycerol to hydrolyze the sn-3 fatty acyl group. 
Finally, the sn-2 fatty acyl group is hydrolyzed by monoacylglycerol lipase. Free fatty acids and 
glycerol, the net products of lipolysis, are liberated and released from cells. The liberated fatty 
acids may reenter the adipocyte intracellular fatty acid pool where they may either be reesterified 
to neutral lipids or be utilized for oxidation in mitochondria to generate ATP. However, adipocytes 
cannot metabolize the glycerol produced resulting from TAG lipolysis because adipocytes lack 
glycerol kinase, which is responsible for de novo synthesis of TAG and glycerol-phospholipids 
(Mersmann and Smith, 2005; Walther and Farese, 2009). 
In cattle and sheep, isoproterenol, a non-selective ß-agonist, shows a strong lipolytic effect; 
terbutaline, a ß2-agonist, shows a slight lipolytic effect; and dobutamine, a ß1-agonist, has no effect 
on lipolysis in heifer and lambs (Ferlay and Chilliard, 1999; Ferlay et al., 2001). In addition, 












THE LENTIVIRAL-SYSTEM CONSTRUCTION FOR HIGHLY EXPRESSED PORCINE 




Epidemiological studies and randomized controlled studies have provided conflicting 
evidence regarding dietary and risk for cardiovascular disease (CVD). Whereas epidemiological 
studies (Posner et al., 1991; Xu et al., 2006) indicated significant positive associations between the 
incidence of CVD and the proportion of dietary energy intake from monounsaturated fatty acids 
(MUFA), randomized controlled studies indicated that increasing dietary oleic acid (18:1n9) 
reduced risk factors for CVD (Kris-Etherton et al., 1999; Adams et al., 2010; Gilmore et al., 2011; 
Gilmore et al., 2013).  However, endogenously produced oleic acid may promote obesity, hepatic 
steatosis, and lipid accumulation in muscle (Ntambi and Miyazaki, 2004; Hulver et al., 2005). 
The conversion of saturated fatty acids (SFA) to MUFA by the fatty acid Δ9 desaturase, 
stearoyl-CoA desaturase-1 (SCD1) accounts for the majority of MUFA in porcine muscle and 
adipose tissue (St. John et al., 1991; Klingenberg et al., 1995). SCD1 is also responsible for the 
conversion of trans-vaccenic acid to its corresponding conjugated linoleic acid (CLA) isomer, 18:2 
cis-9, trans-11 CLA (Ntambi and Miyazaki, 2003). In laboratory rodents, SCD1 is expressed in 
both liver (Ntambi, 1992; Waters and Ntambi, 1994) and adipose tissue (Kang et al., 2004), 
although SCD1 activity is at least two orders of magnitude higher in mouse liver than in adipose 
                                                 
 Reprinted from “The lentiviral-system construction for highly expressed porcine scd1 and functional 
characterization in stably transduced porcine sk6 cells” by Hwang et al., Lipid, In press, 2019.   
 
 22 
tissue (Enser, 1979). Oleic acid is the preferred substrate for acyl-CoA:cholesterol acyltransferase 
(Landau et al., 1997; Miyazaki et al., 2000), and adipose tissue stores cholesterol primarily as 
cholesterol ester (Sweeten et al., 1990). 
We have used the pig as a model to document the effects of dietary fatty acids on lipid 
metabolism (St. John et al., 1987a; Smith et al., 1996a; Smith et al., 1996b; Smith et al., 1999; 
Demaree et al., 2002; Smith et al., 2002; King et al., 2004; Go et al., 2012). Feeding palmitic acid 
(16:0) or a combination of myristoleic acid (14:1n5) plus palmitoleic acid (16:1n7) to pigs 
depressed lipid synthesis from glucose and subcutaneous adipocyte size (Smith et al., 1996b), 
whereas the myristoleic/palmitoleic acid combination increased plasma LDL cholesterol (Smith et 
al., 1996a).  SCD1 activity in porcine adipose tissue increases when fed a starch-based diet, and is 
greater in obese pig adipose tissue than in lean pigs (Smith et al., 1999).  In contrast to rodents, 
porcine adipose tissues exhibit substantially higher SCD1 catalytic activity than liver or intestinal 
mucosal cells (Klingenberg et al., 1995).  However, we demonstrated that there were no differences 
in SCD1 gene expression across liver, muscle, adipose tissue, and intestinal mucosal cells (Go et 
al., 2012), suggesting translational or post-translational control of activity.   
SCD1 expression was previously demonstrated in mouse kidneys, which was depressed 
during the onset of diabetes (Wilson et al., 2003). SCD1 is expressed in proximal kidney tubule 
cells, and SCD1 expression is increased during uromodulin-associated kidney disease (Horsch et 
al., 2014). The predominant isoform of SCD in mouse kidneys is SCD1 (Ntambi and Miyazaki, 
2003), and SCD1 is upregulated in the glomeruli of patients with diabetic nephropathy (Sieber et 
al., 2013). Palmitic acid induces glomerular podocyte death, whereas palmitoleic acid and oleic 
acid attenuate palmitic acid-induced lipotoxicity in podocytes (Sieber et al., 2010).   
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Measurement of SCD1 activity requires large amounts of microsomal protein and the assay 
inherently has high intra-sample variability (St. John et al., 1991; Yang et al., 1999; Smith et al., 
2002; Chung et al., 2007). SCD1 activity has not been described in porcine kidney cells.  The 
porcine SK6 cell line has been used to study viral infections such as hog cholera (Terpstra et al., 
1990) and classical swine fever (van Gennip et al., 1999; Chen et al., 2015). However, to date, 
SCD1 expression has not been documented in SK6 cells. We predicted that endogenous SCD1 
expression would be low in this kidney cell line, and hypothesized that SCD1 expression would 
be upregulated in SK6 cells by exposure to palmitic acid. Therefore, one objective of this study 
was to establish an effective and highly reproducible means of estimating functional SCD1 
catalytic activity. To accomplish this goal, we used SK6 cells, which do not contain detectable 
SCD1 mRNA or protein and further, SK6 cells transduced with an inducible pSCD1 lentiviral 
construct. SCD1-transduced SK6 cells effectively converted supplemental palmitic acid to 
palmitoleic acid, consistent with profound increases in SCD1 mRNA and protein. The long-term 
goal of this research is to generate transgenic pigs for the study of obesity and muscle and liver 
steatosis using the lentiviral constructs utilized in this study. 
 
Materials and Methods 
Cell Lines 
Swine kidney 6 cells (SK6) were obtained from the Foreign Animal Disease Diagnostic 
Laboratory (APHIS) at Plum Island Animal Disease Center (PIADC), Greenport, NY. Cells were 
cultured under standard tissue culture conditions, using minimum essential media (MEM) (Life 
Technologies/Invitrogen, Grand Island, NY) containing 10% FBS (Atlanta Biologicals, Flowery 
Branch, GA) and supplemented with 1% antibiotics (Life Technologies/Invitrogen, Grand Island, 
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NY) and 1% non-essential amino acids. Lenti-X 293T cell line (Clontech Laboratories, Inc., 
Mountain View, CA) is a HEK cell line, transformed with adenovirus type 5 DNA that also 
expresses the SV40 large T antigen. The cell line was subcloned for high transfectability and high-
titer virus production. This cell line was used to produce recombinant lentiviruses. These cells 
were also cultured under similar standard conditions as explained above.  
 
Generation of all-in-one Tet Inducible bidirectional lentiviral vector for pSCD1 overexpression 
The all-in-one bidirectional lentiviral vector system was derived from pLVX-Tre3G-IRES 
(Clontech Laboratories Inc., Mountain View, CA) (Figure 1a) and consisted of a CMV-driven rt-
TA (Tet-On 3G transactivator) in the reverse orientation with gene of interest (GOI) under the 
influence of Tre3G (TRE) promoter in forward direction (Figure 1b). The promoters (CMV and 
Tre3G) in bidirectional orientation were separated by a ubiquitous chromatin opening element 
(UCOE) known to promote sustained and reliable transgene expression by resisting DNA 
methylation (Zhang et al., 2010). In the presence of doxycycline, the rt-TA (Tet-On 3G) is 
expressed, which in turn binds to tetracycline responsive element (Tre3G) to drive the expression 
of the transgene. 
The full-length coding sequence of porcine SCD1 was amplified from reverse transcribed 
porcine mRNA using primers listed in Table 2. The amplified pSCD1 gene was inserted at BamHI-
NotI sites of a bidirectional lentiviral vector, pLVX-UCOE-Tre3G-GOI, under the influence of 
Tre3G in forward orientation followed by IRES-GFP to create pLVX- UCOE-Tre3G-pSCD1 
(Figure 1c). The recombinant lentiviral vectors also consisted of a puromycin antibiotic selection 
marker driven by PGK promoter for selection of transduced cells. The correct orientation and 
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integrity of recombinant lentiviral vector was confirmed by restriction enzyme analysis followed 
by DNA sequencing. 
 
 
Figure 1. Schematics of the lentiviral vector constructs for pSCD1 overexpression. SK6 were 
transduced with the bidirectional lentivector construct depicted in Figure 1c followed by 
puromycin selection to generate SK6-I-pSCD1 cells that could be induced with doxycycline to 
express pSCD1 and GFP. The transcription direction of the CMV, Tre3G and PGK promoters are 
indicated with arrows. The lentiviral bidirectional promoter constructs were packaged as 
recombinant lenti viruses in HEK293T cells. (a) Schematics of pLVX-Tre3G-IRES (Clontech). 
(b) Schematics of bidirectional pLVX-UCOE-Tre3G-GOI. (c) Schematics of bidirectional pLVX-
UCOE-Tre3G-pSCD1.  LTR, long-terminal repeat; ψ, packaging signal; Ze, zeocin; rt-TA, Tet 
responsive transactivator; Tre3G, Tet promoter; CMV, cytomegalovirus promoter; PGK, 
Phosphoglyceratekinase promoter; UCOE, ubiquitous chromatin opening element; pSCD1, 













Primers for qPCR  




pGAPDHb NM_001206359.1 F: 5’-TCGGAGTGAACGGATTTG-3’ 
R: 5’-CCTGGAAGATGGTGATGG-3’ 
219 
pYWHAGc XM_005661962.3         F: 5’-TTTTTCCAACTCCGTGTTTCTCT-3’ 
F: 5’-CCATCACTGAGGAAAACTGCTAA-3’ 
75 
pYWHAZd XM_021088756.1         F: 5’-ATGCAACCAACACATCCTATC-3’ 
R: 5’-ATGCAACCAACACATCCTATC-3’ 
178 
Primers for Cloning 
pSCD1 NM_213781.1 F: 5’- ATGCCGGCCCACTTGCTGC-3’ 








apSCD1, porcine stearoyl-CoA desaturase-1; bpGAPDH, porcine glyceraldehyde 3-phosphate 
dehydrogenase; cpYWHAG, porcine tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein gamma; dpYWHAZ, yrosine 3-monooxygenase/tryptophan 5-monooxygenase 





Generation of all-in-one Tet-inducible bidirectional lentiviral vector for knockdown of pSCD1 
To generate the all-in-one bidirectional lentiviral vector system for suppression of pSCD1, 
we utilized the same lentiviral backbone utilized for pSCD1 overexpression, which was modified 
as shown in Figure 2b.  Two different short hairpin RNAs (shRNA1 and shRNA2) were designed 
to target different regions of pSCD1 and a scrambled shRNA was designed as a control. shRNAs 
for pSCD1 were designed using a web-based tool (RNAi Central; 
http://cancan.cshl.edu/RNAi_central/RNAi.cgi?type=shRNA). Each shRNA was cloned using 
second-generation shRNA-mirs by the PCR-based strategy described previously (Silva et al., 
2005) into a non-inducible lentiviral vector (PEG) consisting of a mir (miR30 microRNA) cassette 
(Figure 2a) (Golding and Mann, 2011) to create PEG-pSCD1shRNA1, PEG-pSCD1shRNA2, and 
PEG-scrambled shRNA. The shRNA-mir cassette was cloned into the 3’ UTR of GFP under the 
influence of elongation factor 1 (EF1) promoter for constitutive expression of hairpins (Figure 
2a). The sequences for pSCD1shRNA oligos are listed in Table 2. Restriction enzyme analysis and 
DNA sequencing confirmed all cloned pSCD1shRNAs. The GFP-pSCD1shRNA fragment was 
cut from PEG-pSCD1shRNA and cloned at BamHI-sphI in bidirectional lentiviral vector pLVX- 







Figure 2. Schematics of the lentiviral vector constructs for pSCD1 knockdown. The 
transcription direction of the CMV, Tre3G,  PGK and EF1α promoters are indicated with arrows. 
The lentiviral bidirectional constructs (pLVX-Tre3G-GFP-pSCD1shRNA and pLVX-UCOE-
Tre3G-GFP-pSCD1shRNA) and lentiviral unidirectional construct (PEG-pSCD1shRNA) were 
packaged as recombinant lentiviruses in HEK293T cells. (a) Schematics of PEG-pSCD1shRNA. 
(b) Schematics of bidirectional pLVX-UCOE-Tre3G-pSCD1shRNA.  LTR, long-terminal repeat; 
ψ, packaging signal; Ze, zeocin; rt-TA, Tet responsive transactivator; Tre3G, Tet promoter; CMV, 
cytomegalovirus promoter; PGK, phosphoglyceratekinase promoter; UCOE, ubiquitous chromatin 
opening element; pSCD1, porcine stearoyl-CoA desaturase-1; EF1α, elongation factor ; GFP, 
green fluorescent protein ; miR , flanking and loop sequences from an endogenous miRNA which 
directs the excision of the engineered miRNA from a pri-miRNA. 
 
Production of recombinant lentiviral vector stock 
The lentiviral vector stocks were generated by triple plasmid co-transfection of HEK293T 
cells, with a Calcium Phosphate Transfection Kit (Life Technologies, Grand Island, NY) or X-
Fect Transfection Reagent (Clontech Laboratories Inc., Mountain View, CA). Briefly, the 
HKE293T cells were co-transfected with bidirectional lentiviral vectors expressing the pSCD1 or 
pSCD1shRNA cassettes along with envelope plasmid pMD.G and packaging plasmid pCMV8.91 
described previously (Case et al., 1999).  A total of 13.8 µg of vector, 10.2 µg of pCMV8.91 and 
6 µg of pMD.G plasmids were used to transfect a 10 cm tissue culture dish. The transfection 
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efficiency was determined by green fluorescent protein (GFP) expression by fluorescence 
microscopy. The medium was replaced with DMEM after 24 h of transfection. The supernatant 
fractions were harvested 48 and 72 h after transfection, centrifuged at 1,000 x g for 10 min and 
filtered through a 0.45 µm polyethersulfone (PES) (low protein binding) filter. The recombinant 
lentiviral vector stocks were concentrated using Lenti-X™ Concentrator (Clontech Laboratories 
Inc., Mountain View, CA) as per manufacturer’s protocol. Briefly, the lentiviral vector particles 
were concentrated by combining 1 volume of Lenti-X Concentrator with 3 volumes of clarified 
supernatant fraction followed by incubation at 4°C for 60 min and centrifugation at 1,500 x g for 
45 min. The supernatant fraction was removed carefully, and pellet was resuspended in 1/100th of 
the original volume using complete DMEM.  
Viral titers were determined by standard viral titration protocol which consists of 
transducing SK6 cells with serial dilutions of these recombinant lentivirus stocks and then 
selecting for stable transductants with antibiotic (3 g/mL of puromycin) and counting the 
resulting cell colonies. This dose of puromycin was selected based on the kill curve in unmodified 
SK6 cells. The titer of virus corresponds to the number of colonies generated by the highest 
dilution. Viral titers were 4.5 x 105 colony forming units (CFU). 
 
Generation of transgenic SK6 expressing pSCD1 
SK6 cells were transduced with recombinant lentiviral stocks at the multiplicity of 
infection (MOI) of 1 along with 4 g/mL of polybrene. Media was replaced 24 h after transduction 
with DMEM supplemented with 10% tetracycline free heat inactivated FBS. After 48 h, transduced 
cells were subjected to puromycin drug selection at the dose of 3 g/mL for 7-14 d to obtain stable 
transductants. Puromycin-resistant colonies were picked using cloning cylinders and expanded in 
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presence of puromycin at a maintenance dose of 0.25 g/mL. These colonies were selected and 
expanded to create SK6-I-pSCD1 cells. SK6-I-pSCD1 cells were induced with dox at a dose of 4 
g/mL for transgene (pSCD1 and GFP) expression. Transduction efficiency in SK6 cells upon 
induction with dox was estimated based on GFP fluorescence. This dose of dox was optimized in 
SK6 cells by a dose response experiment. Dox was replenished in media every 48-72 h.  
 
 
Testing shRNA knockdown of pSCD1 
Inserting shRNA into the mir cassette ensured efficient processing of the expressed 
hairpins (Manjunath et al., 2009). The efficiency of the hairpins was validated in SK6-I-pSCD1 
cells which were overexpressing pSCD1, since SK6 cells exhibited very low or undetectable levels 
of pSCD1. SK6-I-pSCD1 cells in 6-well plates were induced pSCD1 and GFP expression 48 h 
before transfection by induction with dox. Following 48 h, the cells were mock transfected or with 
2 g/mL of PEG-pSCD1shRNA1, PEG-pSCD1shRNA2 and PEG-scrambled shRNA using 
Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA). The medium was replaced with 
DMEM after 24 h of transfection. The cells were harvested 48 h post-transfection for RNA and 
protein analysis.  
 
Quantitative real-time RT-qPCR 
Total RNA was isolated from cells using the RNAeasy kit (Qiagen, Valencia, CA) as per 
manufacturer’s protocol followed by DNAseI (Sigma-Aldrich, St. Louis, MO) treatment. The 
DNAseI treated RNA was quantified and used to produce cDNA with the qScript kit (Quanta 
Biosciences, Gaithersburg, MD) according to the manufacturer’s instructions. Relative mRNA 
levels were determined by comparative threshold cycle (CT) analysis (Livak and Schmittgen, 
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2001) for pSCD1 using the PerfeCTa® SYBR® Green FastMix, ROX (Quanta Biosciences, 
Gaithersburg, MD) on a ABI Prism 7500 thermocycler (Applied Bio systems, Carlsbad, CA). 
Porcine GAPDH, YWHAZ and YWHAG were used as endogenous controls for these experiments. 
Relative mRNA levels were expressed as fold change over transfection control. The primers used 
in these studies are listed in Table 2. 
 
Western blot 
Protein concentrations in samples were measured using Pierce™ BCA Protein Assay Kit 
(Life Technologies, Grand Island, NY).  Total protein (30 µg) was separated on a 12% SDS-PAGE 
gel at constant current. Proteins in the gel were transferred onto a polyvinylidene fluoride 
membrane using Mini Trans-Blot (Bio-Rad, Hercules, CA). Porcine SCD1 and ß-actin were 
detected using a polyclonal anti-SCD1 (2 µg/mL) and anti-ß-actin antibodies (0.2 µg/mL) (Abcam, 
Cambridge, MA). For quantification of SCD1 protein, the pixel intensity of SCD1 signal was 
normalized to that of β-actin for each sample using Image J software. 
 
Palmitic acid treatment and fatty acid analysis 
SK6 and SK6-I-pSCD1 cells (dox+ and dox-) in T-175 flasks were mock treated or treated 
with a SCD1 inhibitor (ab 142089, Abcam, Cambridge, MA) at a dose of 2 µM. Twenty-four hours 
later, cells were exposed to 50 µM palmitic acid or ethanol (control). Six hours after palmitic acid 
treatment, cells were harvested for fatty acid, RNA, and protein analyses. The extraction of fatty 
acids was conducted by a modification of the method of (Folch et al., 1957). Total lipids from SK6 
cells were extracted in chloroform/methanol (2:1, vol/vol) and then methylated by 14% (wt/vol) 
boron trifluoride-methanol (Sigma-Aldrich Corp, St. Louis, MO). The fatty acid methyl esters 
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(FAME) were analyzed using a gas chromatography equipped with a CP-8200 auto sampler and 
flame ionization detector (FID) (Varian CP-3800 GC system, Varian Inc., Walnut Creek, CA). 
FAME were separated on a CP-Sil88 fused silica capillary column (100 m x 0.25 mm internal-
diameter with 0.2-mm film thickness), with hydrogen as the carrier gas at a flow rate of 35 mL/min 
(split ratio 20:1) (Chrompak Inc., Middleburg, Netherlands). The oven temperature was 
programmed to increase from 150°C at 5°C/min to 220°C and held for 22 min. Front inlet and FID 
temperature were at 270°C and 300°C, respectively. Individual fatty acid peaks were identified by 
genuine external standard GLC-68D (Nu-Chek Prep, Inc., Elysian, MN) and calculated as the ratio 
of individual areas to that of total identified fatty acids. 
 
Statistical analyses 
Statistical analysis was performed using either Student’s t-test or one-way analysis of 
variance followed by Tukey’s Multiple Comparison Test (Graph Pad Prism 6.0, Graph Pad 
Software, La Jolla, CA). Means for fatty acid percentages were compared by analysis of variance 
and when significant (P < 0.05), means were separated by Fisher’s Protected LSD method. All the 
experiments were performed in triplicates with at least two independent runs. The data are 




SCD1 is a key enzyme in lipid metabolism and plays a major role in health and disease 
states of animals and humans. The main aim of this study was to generate porcine cell culture 
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models for sustained over expression or suppression of porcine SCD1 in a controlled manner (dox 
inducible) and to assess their functionality in lentiviral-transduced SK6 cells. 
 
 
Over expression of pSCD1 in transduced SK6 cells 
The expression of pSCD1 in lentiviral-transduced SK6 cells (SK6-I-pSCD1 cells) was 
validated by both RT-qPCR and western blot. SK6-I-pSCD1 cells were subjected to puromycin 
selection at a dose of 3 g/mL, which resulted in death of majority of the SK6 cells within 3-4 
days, with only SK6-I-pSCD1 cells surviving in colonies. These colonies were expanded in 
presence of puromycin (3 g/mL) for 10-14 days and thereafter they were grown in maintenance 
dose of puromycin (0.5 g/mL). Two colonies (Cl 1 and Cl 2), seeded in 6-well plates were 
induced with different doses of dox as indicated in Fig. 3a to test the dose response. Twenty-four 
hours after dox induction (dox+), GFP expression was monitored under a microscope. Both Cl 1 
and Cl 2 exhibited GFP expression upon induction with dox. Cells were harvested for RNA 48 h 
post-dox induction for RT-qPCR. A dose-dependent increase in pSCD1 transcripts was seen in 
Fig. 3a. There was a significant increase in pSCD1 mRNA levels in both Cl 1 and Cl 2 upon 
induction with dox at 2 μg/mL (> 600-fold increase) and 4 μg/mL (> 800-fold increase) as 
compared to uninduced (dox-) SK6-I-pSCD1 cells (Figure 3a). The mRNA levels of pSCD1 Cl 2 
at either level of dox was not different than Cl 1 (Figure 3a). However, in Cl 1, 4 µg/mL dox 
increased the level of pSCD1 mRNA compared to the lower dose (P < 0.05). To determine the 
optimum time after dox induction for harvesting and analyzing our samples for transgene (pSCD1) 
expression, we performed a time-response study. 
Cells from two transgenic colonies, Cl 1 and Cl 2, were seeded in 6-well plates and induced 
with dox at a dose of 4 μg/mL. The samples were harvested at indicated time points after dox 
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induction (Figure 3b). Total RNA was extracted for RNA analysis by RT-qPCR. There was a 
significant increase in pSCD1 transcripts in transduced Cl 1 and Cl 2 cells upon induction with 
dox as compared to induction without dox in SK6-I-pSCD1 cells at all time points (Figure 3b). 
The increase in pSCD1 mRNA levels in SK6-I-pSCD1 cells (dox+) was detected as early as 24 h 
post-dox induction and maintained until 72 h (Figure 3b). There was a substantial decrease, though 
not significant, in the pSCD1 mRNA levels 96 h after addition of dox to culture media (Figure 3b), 
suggesting that fresh dox has to be replenished after every 48-72 h in the culture media.  
The expression of pSCD1 also was confirmed by western blot analysis (Figure 3c), wherein 
a pSCD1-specific band corresponding to 37 kDa was seen in cell lysates of SK6-I-pSCD1 cells 
induced with dox (Figure 3c). Interestingly, no band was observed in cell lysates of normal SK6 
cells, indicating that pSCD1 is expressed at very low or undetectable levels in these cells (Figure 




Figure 3. Doxycycline-induced expression of porcine SCD1 in SK6-I-pSCD1 cells. SK6 cells 
were transduced with recombinant  lentivirus, pLVX-UCOE-Tre3G-pSCD1, selected with 
puromycin  (3 µg/ml) and clonally expanded to create SK6-I-pSCD1 cells which is overexpressing 
pSCD1. (a) Dose response in two colonies of SK6-I-pSCD1 cells. (b) SK6-I-pSCD1 cells were 
induced with dox at the dose of 4 µg/ml and  total RNA was extracted  at indicated time points 
from two colonies of SK6-I-pSCD1 cells to measure mRNA levels of pSCD1 by RT-qPCR. mRNA 
levels were normalized to the geometric mean of endogenous porcine GAPDH, YWHAG and 
YWHAZ and are represented as fold increase compared to control. (c) pSCD1 protein levels were 
detected by western blot using anti-SCD1 or anti-ß-actin antibodies. dox, doxycycline; SK6-I-
pSCD1, SK6 cells overexpressing pSCD1. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
shRNA effectively suppressed expression of pSCD1 
Transfection of SK6-I-pSCD1 cells (overexpressing pSCD1) with PEG-pSCD1shRNA1 or 
PEG-pSCD1shRNA2 led to significant knockdown of pSCD1 as compared to PEG-scrambled 
shRNA (Figure 4a). A similar trend was observed with western blot analysis (Figure 4b). PEG-
pSCD1shRNA2 showed a better knockdown efficiency of pSCD1 as compared to PEG-
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pSCD1shRNA1. A significant decrease in pSCD1 protein expression was observed in cell lysates 
of PEG-pSCD1shRNA2 as compared to PEG-scrambled shRNA (Figure 4c). Therefore, we used 
PEG-pSCD1shRNA2 in our inducible all-in-one lentiviral system and for further experiments. To 
generate the inducible all-in-one lentiviral system for knocking down pSCD1, we cloned the GFP-
pSCD1shRNA2-mir fragment from PEG-pSCD1shRNA2 in bidirectional pLVX-UCOE-Tre3G-
GOI at BamHI-SphI sites replacing GOI-IRES-GFP to create bidirectional pLVX-UCOE-Tre3G-






Figure 4. Knockdown of pSCD1 in SK6 and SK6-I-pSCD1 cells overexpressing pSCD1. SK6 
cells (6-well plates) or SK6-I-pSCD1 cells overexpressing pSCD1 were mock transfected or  
transfected with lentivector shRNA constructs, PEG-SCD1shRNA1, PEG-SCD1shRNA2 or PEG-
Scrambled shRNA at a dose of  2.0 µg using lipofectamine 3000. Transfection efficiency was 
determined next day by GFP expression. Cells were harvested 48 h post-transfection for RNA and 
protein analysis by RT-qPCR and western blot. (a) pSCD1 mRNA levels were normalized to the 
geometric mean of endogenous porcine GAPDH, YWHAG  and YWHAZ and are represented as 
percentage knockdown. The data represent means ± SE from three independent experiments 
performed in duplicates. (b) Knockdown of pSCD1 protein by western blot analysis using anti-
SCD1 or anti-ß-actin antibodies. (c) pSCD1 protein levels detected by western blot were quantified 
and normalized to ß-actin from three independent experiments and expressed as means ± SE 
(Image J). dox, doxycycline; SK6-I-pSCD1, SK6 cells overexpressing pSCD1. *P < 0.05, **P < 




Functional assessment of pSCD1 in SK6-I-pSCD1cells 
The functionality of pSCD1 in SK6 and SK6-I-pSCD1 cells was assessed by fatty acid 
analysis in absence or presence of supplemental palmitic acid and a SCD1 inhibitor. We previously 
had demonstrated that supplemental palmitic acid enhanced bovine SCD1 gene expression, 
putatively through interaction with the intrinsic SCD1 promoter (Choi et al., 2016). Therefore, we 
first established the effect of supplemental palmitic acid and SCD1 inhibitor treatment in SK6 and 
SK6-I-pSCD1cells on pSCD1 gene expression. We found no significant difference in pSCD1 
transcript (Figure 5a) in absence or presence of palmitic acid (50 µM) and SCD1 inhibitor (2 µM), 
indicating that supplemental palmitic acid has no effect on pSCD1 gene expression in the SK6-I-
pSCD1 cell model. However, SCD1 inhibitor significantly decreased pSCD1 protein level in SK6-
I-pSCD1 cells induced with dox (P < 0.05). In the absence of supplemental palmitic acid, palmitic 
acid, stearic acid (18:0), and oleic acid were the most abundant fatty acids in SK6 cells and 
comprised approximately 19, 21, and 29% of total fatty acids (Table 3). Less abundant fatty acids, 
palmitoleic acid and cis-vaccenic acid (18:1n7), comprised approximately 4 and 5%, respectively. 
With the addition of 50 µM palmitic acid, cellular palmitic acid increased to from 19 to 27% of 
total lipids (Table 3).  
The base-catalyzed fatty acid methylation procedure used in this study methylates only 
esterified fatty acids (Smith et al., 1998), so any changes in the proportions of fatty acids with 
treatment reflected alterations in cellular neutral lipids and phospholipids. Proportions of 
palmitoleic acid and cis-vaccenic acid in cellular lipids were highest in SK6-I-pSCD1 cells (dox+), 
and incubated with supplemental palmitic acid (Figure 6a). Transfection with PEG-
pSCD1shRNA2 followed by treatment with SCD1 inhibitor strongly depressed the proportions of 
palmitoleic acid and cis-vaccenic acid (Figure 6b). Palmitoleic acid is produced endogenously 
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from the ∆9 desaturation of palmitic acid, which subsequently is elongated to cis-vaccenic acid. 
Therefore, depression in the proportion of these n-7 fatty acids under these conditions represents 
inhibition of pSCD1 gene expression plus reduction in pSCD1 catalytic activity. 
In the absence of dox, supplemental palmitic acid increased the proportion of cellular 
palmitic acid (P < 0.05) and induction with dox followed by treatment with the SCD1 inhibitor 
further increased palmitic acid (Table 3), indicating low pSCD1 activity under both conditions. 
The highest concentration of cellular palmitoleic acid was observed in SK6-I-pSCD1 cells (dox+) 
supplemented with palmitic acid. 
Palmitoleic acid is inversely proportional to stearic acid (Figure 6c), as the concentration 
of each is reciprocally established by SCD1 activity. Therefore, the palmitoleic:stearic acid ratio 
(an index of SCD1 activity), was highest in SK6-I-pSCD1 cells (dox+), incubated with 
supplemental palmitic acid (Table 3). Similarly, the fold increase in palmitoleic acid was greatest 
in SK6-I-pSCD1 cells (dox+) incubated with supplemental palmitic acid (Figure 6d). The fold 
increase in palmitoleic acid in SK6-I-pSCD1 cells was depressed by transfecting these cells with 





Figure 5. pSCD1 in SK6 and SK6-I-pSCD1 cells after palmitic acid treatment. SK6 cells or 
SK6-I-pSCD1 cells were treated with 50 µM palmitic acid or  ethanol (control). Six hours after 
palmitic acid treatment, cells were harvested for RNA and protein analyses. (a) mRNA levels were 
normalized to the geometric mean of endogenous porcine GAPDH, YWHAG  and YWHAZ and are 
represented as fold increase compared to control. (b) western blot analysis using anti-ß-actin or 
anti-SCD1 antibodies. (c) SCD1 protein levels detected by western blot were quantified and 
normalized to ß-actin from three independent experiments and expressed as means ± SE (Image 
J).  abcMeans within with common superscripts are not different (P > 0.05). 16:0, palmitic acid; 





Figure. 6. Partial gas/liquid chromatograms showing FAME profiles of total cellular lipids 
of SK6-I-pSCD1 cells. SK6 or SK6-I-pSCD1 cells were mock treated or treated with SCD1 
inhibitor at a dose of 2 µM. Twenty-four hours later, cells were exposed to 50 µM palmitic acid 
or ethanol (control). Following 6 h after palmitic acid treatment, cells were harvested for fatty 
acid analysis. Total lipids from cells were extracted in chloroform/methanol (2:1, vol/vol) and 
then methylated by 14% (wt/vol) boron trifluoride-methanol. The fatty acid methyl esters 
(FAME) were analyzed using a gas chromatography equipped with a CP-8200 auto sampler and 
flame ionization detector (FID). (a) FAME from SK6-I-pSCD1 cells treated with palmitic acid. 
(b) FAME from SK6-I-pSCD1 cells transfected with PEG-pSCD1shRNA2 and treated with 
palmitic acid plus SCD1 inhibitor. The peaks in A and B reflect FAME detector signals (mEV).  
(c) Relationship between cellular palmitoleic acid and stearic acid.  Data are proportions of 
palmitoleic acid (16:1n7) as a function proportion of stearic acid (18:0). (d) Fold change in 
palmitoleic acid. The data represent means ± SE from three independent experiments. abcMeans 
within with common superscripts are not different (P > 0.05). 16:0, palmitic acid; dox, 




Table 3. Fatty acid composition of SK6 cells and SK6-I-pSCD1 cells. SK6 or SK6-I-pSCD1 cells 
(with or without dox) were incubated in the absence and presence of palmitic acid (16:0) and SCD1 
inhibitor.  
 
Fatty acid composition, 
mg/100 mg total fatty acids 
16:1n7/ 
18:0 














SK6 + 16:0 
 
27.03b   3.49de 20.70abc 29.15cd 0.169bc 
SK6 + 16:0  
+ SCD1 inhibitor 
26.26bc   2.64e 23.07a 26.80de 0.117c 
 












SK6-I-pSCD1/dox(-) + 16:0 
 
24.67bcd   6.30c 16.30cd 29.21cd 0.401b 
SK6-I-pSCD1/dox(-) + 16:0    
+SCD1 inhibitor 
29.91ab   3.40de 20.53abc 24.38de 0.166b 
 












SK6-I-pSCD1/dox(+) + 16:0 
 
25.00bcd 13.49a 14.08d 25.97de 0.999a 
SK6-I-pSCD1/dox(+) + 16:0      
+ SCD1 inhibitor 
34.28a   6.48c 16.41cd 22.27e 0.397b 
 


























SK6-I-pSCD1/dox(+) + 16:0      
+ pSCD1shRNA2 
+ SCD1 inhibitor 
 
23.97bcd 























0.0012 0.0001 0.0136 0.004 0.0001 







The conventional TET On/TET Off inducible lentiviral vector systems generally used to 
produce transgenic animals are based on two separate lentiviral vectors (Koponen et al., 2003; 
Park, 2007; Sheng et al., 2010). One vector encodes the inducible transcriptional activator 
(tetracycline-controlled transactivator protein (rt-TA)) and the other vector encodes the gene of 
interest under the influence of a tetracycline-responsive element (TRE). The expression of the 
transgene can thus be regulated in a quantitative and reversible manner by exposing the transgenic 
animal to varying amounts of tetracycline or its derivatives (dox) (Sheng et al., 2010). In the 
presence of dox, the rt-TA (Tet-On 3G) gets expressed, which in turn will bind to tetracycline 
responsive element (Tre3G) to drive the expression of transgene. However, the efficiency of the 
two-vector system is low as co-transduction of the target cells with both vectors is required. In that 
regard, our combination of the two vectors into one contributed to improved transduction 
efficiency and, in turn, increased porcine SCD1 expression in transduced SK6 cells (SK6-I-pSCDl 
cells).    
The SCD1 isoform is the most abundant in lipogenic tissues and is common to most 
species. The pSCD1 gene has been mapped to chromosome 14 (Uemoto et al., 2012), and has > 
80% homology with other mammalian SCD1 genes (Ren et al., 2004).  As in humans, the only 
other SCD isoform identified in livestock species is SCD5, which has 90% homology with human 
SCD5 (Lengi and Corl, 2007, 2008). SCD5 gene expression is primarily limited to the brain, 
although low levels of SCD5 mRNA have been detected in liver and muscle (Lengi and Corl, 2007, 
2008). 
Proportions of the endogenously produced fatty acids in SK6 cells were similar to fatty 
acid proportions observed in porcine tissues (St. John et al., 1987b; Klingenberg et al., 1995; Go 
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et al., 2012). Thus, oleic acid was the most abundant MUFA and palmitic acid the most abundant 
SFA in SK6 cells. The high relative abundance of stearic acid indicated an active fatty acid 
elongase under all incubation conditions. This was supported by the relative increases in cis-
vaccenic acid in SK6-I-pSCD1 cells, which provided evidence that some portion of the palmitoleic 
produced by the ∆9 desaturation of supplemental palmitic acid was elongated. However, in spite 
of the relative abundance of oleic and cis-vaccenic acid, in SK6 cells we detected only small 
amounts of pSCD1 mRNA, and pSCD1 protein was below detection limits by western blot. 
Porcine SCD1 protein also was not detectable in SK6-I-pSCDl cells in the absence of dox, even 
though pSCD1 mRNA levels were detectable. The small increases in pSCD1 mRNA and the 
significant increases in palmitic and cis-vaccenic acid in SK6-I-pSCD1 cells (dox-) indicates that, 
even in the absence of dox, there was some functional pSCD1 gene expression. We interpret this 
to mean that post-transcriptional regulation of pSCD1 mRNA may control protein levels and that 
even undetectable levels of pSCD1 are catalytically active.   
The SCD1 inhibitor effectively decreased proportions of palmitoleic acid and cis-vaccenic 
acid. In previous research we have used the palmitoleic:stearic acid ratio as an index of SCD1 
catalytic activity (Smith et al., 2006).  Only small amounts of palmitoleic and stearic acid naturally 
occur in diets of animals, and dietary factors that promote SCD1 activity increase tissue 
concentrations of palmitoleic acid and concomitantly decrease stearic acid. Similarly, in the 
current study, SK6 cells had the highest proportions of stearic acid and lowest proportions of 
palmitoleic acid; the converse was true for SK6-I-pSCD1 cells incubated with dox. Essentially 
identical results were obtained when data were expressed as fold increase in palmitoleic acid. 
Previous researchers have transfected cells with SCD1 with varying results. Lu et al. (2014) 
demonstrated that transfection of bone marrow mesenchymal stem cells with SCD1 enhanced 
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SCD1 gene expression, but did not document changes in fatty acid composition (Lu et al., 2014). 
Nakaya et al. (2013) transfected 293A macrophages with mouse Scd1 and demonstrated small but 
significant increases in HDL-mediated cholesterol efflux (Nakaya et al., 2013). However, neither 
palmitoleic nor oleic acid proportions were increased in the SCD1 transgenic macrophages. Wu et 
al. (2010) demonstrated that SCD1 transfection of human embryo kidney (HEK) 293 cells 
increased palmitoleic acid, cis-vaccenic acid, and cis-9, trans-11 conjugated linoleic acid (CLA) 
(all products of SCD activity) by two- to three-fold (Wu et al., 2010). Wang et al. (2014) reported 
that an SCD1 mammary-specific vector caused a 50% increase in palmitoleic acid and an 11% 
increase in oleic acid in goat ear skin-derived fibroblastic cells (Wang et al., 2014). We attribute 
the profound increases in palmitoleic acid (four-fold) in the current study to the stability of our 
SK6-I-pSCD1 cells. 
Collectively, these data indicate that our lentiviral expression system was successfully 
established, and thereby stably and functionally expresses pSCD1 in SK6 cells. The lentiviral 
constructs utilized in this study can be further utilized to generate transgenic animals or other cell 
lines to enhance our understanding of the contribution of fatty acid desaturation to the promotion 





CHARACTERIZATION OF ß-ADRENERGIC RECEPTORS IN BOVINE 
INTRAMUSCULAR AND SUBCUTANEOUS ADIPOSE TISSUE 
 
Introduction 
For more than three decades, the mechanism of action of ß-adrenergic receptor (ß-AR) 
agonists (i.e., cimaterol, clenbuterol, ractopamine, and zilpaterol) has been studied extensively in 
livestock species (i.e., cattle, pigs, chickens, and sheep). Depending on species and compounds, ß-
AR agonists can cause a considerable increase in carcass muscle mass and a decrease in fat 
accumulation, thus promoting the production of lean meat as a source of high quality protein 
(Dalrymple et al., 1984; Jones et al., 1985; Moser et al., 1986; Coleman et al., 1988; Miller et al., 
1988; Schiavetta et al., 1990; Allen et al., 2009; Elam et al., 2009). Decreased lipid in adipose 
tissue occurs through the ß-adrenergic receptors (ß-AR)/adenylyl cyclase (AC)/cAMP-dependent 
protein kinase A (PKA) signaling cascade, in turn activating perilipin and hormone-sensitive lipase 
(Wallukat, 2002).  
Three subtypes of ß-AR (ß1-AR, ß2-AR, and ß3-AR) are expressed in tissues of most 
species, and the distribution and specificity for synthetic ligands in adipose tissue differs widely 
among species. For example, the most predominant subtype is ß2-AR in bovine adipose tissue, 
whereas ß1-AR is the primary subtype in porcine adipose tissue (Sillence and Matthews, 1994; 
McNeel and Mersmann, 1999). For example, the synthetic ligand, ICI118,551 is a selective 
antagonist for ß2-AR in both bovine skeletal muscle and adipose tissue, while it has no effect on 
ß2-AR in porcine adipose tissue (Sillence and Matthews, 1994; Mersmann, 1998).  
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Recently, a new synthetic ß-AR ligand, lubabegon fumarate (as known as ExperiorTM) has 
been developed by Elanco Animal Health. Preliminary data indicated that ExperiorTM acts as ß3-
AR agonist and a ß1-AR and ß2-AR antagonist in Chinese hamster ovary cells (M. E. Spurlock, 
unpublished data). In this study, we tested the hypothesis that bovine adipose tissues express ß3-
AR, and therefore ExperiorTM would exert similar effects in bovine adipose tissue. Furthermore, 
we hypothesized subcutaneous (s.c.) adipose tissue would exhibit grater response to ß3-agonists 
and antagonists than intramuscular (i.m.) adipose tissue. Therefore, the aim of this study was to 
characterize ß-AR in bovine s.c. and i.m. adipose tissues with the use of selective ß-AR agonists 
and antagonists, including ExperiorTM. 
 
Materials and Methods 
Materials 
Lubabegon fumarate (ExperiorTM) and ractopamine hydrochloride (RH) were provided by 
Elanco Animal Health (Elanco Animal Health, Indianapolis, IN). Other drugs and reagents were 
purchased from the following companies: dobutamine, salbutamol, zilpaterol hydrochloride (ZH), 
propranolol, Glycerol Assay Kit and DNAseI (Sigma-Aldrich, St. Louis, MO); L-748,337 and 
BRL-37344 (R&D system, Minneapolis, MN); Cyclic AMP XP® Assay Kit (Cell Signaling 
Technology, Danvers, MA); nonesterified fatty acid (NEFA) kit (Wako Life Sciences, Inc., 
Mountain View, CA); qScriptTM cDNA synthesis kit and Perfecta® SYBR® Green fastmix® 






Angus crossed bred steers (BW = 498 ± 59 kg) (n = 20) were fed a standard, corn-based 
finishing diet at the Texas A&M University McGregor Research Center, McGregor, TX, and then 
transported approximately 190 km to the Texas A&M Animal Science Teaching Research and 
Extension Complex (ASTREC), College Station, TX.  
 
Bovine adipose tissue sampling 
Bovine s.c. and i.m. adipose tissues were obtained as described previously (Miller et al., 
1988; Miller et al., 1989; Miller et al., 1991; Brooks et al., 2011). Briefly, cattle were stunned 
using a captive bolt followed by exsanguination. Immediately after exsanguination, the 
longissimus muscle (LM) overlying s.c adipose tissue from the 8th to 10th thoracic region was 
removed by cutting through the hide immediately lateral to the spinal process. The muscle was 
immediately transported to the laboratory in oxygenated Krebs-Henselheit Ca2+-free bicarbonate 
buffer (KHB) (120 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3; 
37°C; pH 7.4) plus 5 mM glucose and 10 mM HEPES. The time elapsed between the stunning and 
arrival of the LM muscle at the laboratory was less than 20 min.  
 
Adipose tissue explant culture 
Fresh s.c. adipose tissue was cut into small pieces (50 to 100 mg) and i.m. adipose tissue 
was dissected from the LM as described previously (Smith and Crouse, 1984; Miller et al., 1988). 
The s.c. and i.m. adipose tissues were incubated according to three different sets of experimental 
conditions. Experiment 1: small pieces of s.c. and i.m. adipose tissues were pre-incubated in 6-
well tissue culture plates for 30 min at 37°C, 5% CO2 in KHB plus 5 mM glucose, 10 mM HEPES, 
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and 0.5 mM theophylline. After the 30 min pre-incubation, isoproterenol (non-selective ß-AR 
agonist), RH, ZH, ExperiorTM, and BRL-37344 were added to the culture plate wells in a dose-
dependent manner (10-9 to 10-4 M) for an additional 30 min. Experiment 2: the s.c. and i.m. 
adipose tissues were pre-incubated in KHB plus 5 mM glucose, 10 mM HEPES, and 0.5 mM 
theophylline in the presence or absence of either 10 µM L-748,337 or 50 µM propranolol. After 
the 30 min pre-incubation, ExperiorTM was added to the culture plate wells in a dose-dependent 
manner (10-9 to 10-4 M) for an additional 30 min. Experiment 3: the s.c. and i.m. adipose tissues 
were pre-incubated in KHB plus 5 mM glucose, 10 mM HEPES, and 0.5 mM theophylline in the 
presence or absence of 1 µM Experior™ or 1 µM Experior™ plus 10 µM L-748,337. After the 30 
min pre-incubation, either dobutamine (ß1-AR agonist) or salbutamol (ß2-AR agonist) was added 
to the culture plate wells in a dose-dependent manner (10-9 to 10-4 M) for an additional 30 min. 
For all experiments, there were at least three wells per treatment condition. After a total 1 h 
incubation, s.c. and i.m. adipose tissues were homogenized in 1 mL cell lysis buffer (Cell Signaling 
Technology, Danvers, MA) with 1 mM phenymethylsulfony fluoride and centrifuged at 14,000 x 
g for 30 min to remove tissue debris. The supernatant fractions were stored at -80°C until 
subsequent analyses were performed.  
 
Viability of adipose tissue 
To confirm viability of adipose tissue samples following incubation with 
agonists/antagonists, lipogenesis in vitro in s.c. and i.m. adipose tissues was measured at sample 
collection and after 60 min incubation as described previously (May et al., 1995). Briefly, s.c and 
i.m. adipose tissue pieces (~100 mg) were incubated for 0 or 60 min at 37°C with oxygenated 
(95%:5% O2:CO2) KHB (pH 7.35-7.40) plus 5 mM glucose, 5 mM acetate, 10 mM HEPES, 1 μCi 
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[1-14C]acetate (sodium salt) (American Radiolabeled Chemicals, Inc.). After incubation, neutral 
lipids in adipose tissues were extracted (Folch et al., 1957). Total lipids were resuspended in 10 
mL of scintillation cocktail (Bio-safe2, Research Product International Corp., Mount Prospect, IL). 
Radioactivity of lipid extracts was counted with a scintillation counter (Packard 1600TR Liquid 
Scintillation Analyzer, Downers Grove, IL). Results are reported as nmol acetate converted to fatty 
acids/(1 h•100 mg adipose tissue). 
 
Cyclic AMP 
The concentration of cAMP was determined based on the principle of competitive binding 
using the Cyclic AMP XP® Assay Kit according to the manufacturer’s instructions. Briefly, 
cytosolic extracts from s.c and i.m adipose tissue explants were co-incubated in 96-well plates 
with the HRP-linked cAMP substrate coated onto an immobilized rabbit monoclonal cAMP 
antibody at room temperature for 3 h on a horizontal orbital plate shaker. After the reaction, color 
development was measured at 450 nm using an Epoch microplate reader (Biotek Instruments, 
Winooski, VT). All samples analyzed in duplicate. A standard curve and cAMP concentrations 
were calculated using GrapPad Prism 6.04 software (GraphPad Software Inc., San Diego, CA). 
 
Lipolysis  
Lipolysis was measured with a glycerol assay kit and a nonesterified fatty acid (NEFA) kit 
according to the manufacturer’s procedures. In brief, to determine glycerol released from tissue, 
10 µL of the cell extracts was reacted with 100 µL glycerol reaction reagent for 20 min at room 
temperature and the absorbance was read at 570 nm. The glycerol standard from the kit was used 
for the calibration curve. To analyze the level of NEFA released from the adipose tissues, 25 µL 
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of each cell fraction plus 200 μL of the first reagent were incubated for 5 min at 37°C, then 100 
µL of the second reagent was incubated for another 5 min at 37°C. The absorbance was read at 
550 nm. Oleic acid was used to plot a standard curve and to calculate concentration of NEFA in 
the supernatant fractions.   
 
Quantitative real-time RT-qPCR 
Approximately 200 mg of s.c. and i.m. adipose tissues (n = 10) stored at -80°C were used 
to isolate the total RNA using a combination of the Trizol reagent (Invitrogen, Carlsbad, CA) and 
HiBind® RNA mini column (Omega Bio-tek, Inc., Norcross, GA) followed by DNAseI treatment. 
Total RNA was quantified on the NanoDropTM 2000 Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA) and reverse transcription was performed with the qScriptTM cDNA 
synthesis kit. The gene expressions of ß-AR subtypes (ADRB) in s.c. and i.m. adipose tissues were 
analyzed in a CFX384TM Real-Time System (Bio-rad, Hercules, CA) using the Perfecta® SYBR® 
Green fastmix® kit. The different efficacy of cDNA synthesis between samples was normalized 
with three reference genes (RSP9, GAPDH, and SDHA). The relative expression of mRNA was 
determined by the cycle threshold (CT) deviation of an unknown sample versus geometric mean 
of three reference genes and data were presented as 2-ΔCT. The primers used in this assay are listed 







































The data are expressed as means ± SEM. Statistical analysis of the change in gene 
expression obtained by RT-qPCR was tested with a two-sided, unpaired student’s t-test and 
Tukey’s honest significant difference test using JMP Pro 12 software (SAS Institute Inc., Cary, 
NC). A P < 0.05 was considered significant. Otherwise, nonlinear regression model was used to 
test effects on either ß-AR agonists or ß-AR antagonists against lipolytic response. Non-parametric 
Friedman test and one-way analysis of variance (ANOVA) were used where it was appropriate for 
statistical comparison of drug effects with the control and different ß-AR agonists or antagonists 







ß-adrenergic receptor gene profiling in subcutaneous (s.c.) and intramuscular (i.m.) adipose 
tissue 
 All three ADRB genes were detected in bovine s.c.  and i.m. adipose tissues (Figure 7).  
Regardless of adipose tissue type, the predominant ADRB was ADRB2 (P < 0.05). The gene 
expression of ADRB3 was not different from ADRB1 expression in either s.c. or i.m. adipose tissue 
(P > 0.05). The expression of ADRB mRNA were 5.3, 2.9, and 8.3 times higher in s.c. adipose 
tissue than in i.m. adipose tissue for ADRB1, ADRB2, and ADRB3, respectively (P < 0.05). The 
gene expression of the ADRB2 in the s.c. adipose tissue was 5.3 and 3.1 times higher than that of 
ADRB1 and ADRB3, respectively. The ADRB2 mRNA level was 9.6 and 10 times higher compared 
to ADRB1 and ADRB3, respectively, in i.m. adipose tissue. 
 
Figure 7. ß-Adrenergic receptor gene populations in growing steers. The data are expressed as 
means ± SEM (n = 10). ABmeans within s.c. adipose tissue not sharing common superscripts differ 
(P < 0.05). abmeans within i.m. adipose tissue not sharing common superscripts differ (P < 0.05). 






Lipogenesis from acetate increased (P < 0.05) in s.c. adipose tissue was greater following 
incubation for 60 min compared to rates observed in fresh samples (time 0) (Table 5). Rates of 
lipogenesis did not differ (P > 0.05) between fresh and incubated i.m. adipose tissue. We conclude 
that there was no indication of loss of viability during the pre-incubation/incubation period. 
 
 
Table 5. Fatty acid synthesis from acetate in s.c. and i.m. adipose tissue1 
Incubation time, min 0 60 
s.c. 45.56 ± 8.57b 89.63 ± 17.79a 
i.m. 26.65 ± 8.46b 39.21 ± 9.91b 
1Values are means ± SEM for n = 16 steers.  Rates are nmol acetate converted to fatty acids per 
100 mg adipose tissue per 1 h incubation. abMeans with common superscripts do not differ (P > 
0.05).  The main effect of tissue (s.c. vs i.m.) was significant (P = 0.003). 
 
 
Accumulation of cAMP accumulation following treatment with ß-adrenergic receptor agonists 
in s.c. and i.m. adipose tissues 
The non-selective ß-AR agonist, isoproterenol, the ß1-and ß2-AR agonist RH, and the ß2-
AR agonist ZH were used to assess the ß-AR-cAMP signaling cascade in s.c. and i.m. adipose 
tissue. Isoproterenol increased cAMP production in s.c. adipose tissue, indicating that the test 
system effectively activated adenylyl cyclase (Figure 8a). Stimulation of production of cAMP by 
isoproterenol in s.c. adipose tissue reached a plateau at 10-6 M. The EC50 of isoproterenol in s.c. 
adipose tissue was 0.22 µM. The concentration of cAMP in i.m. adipose tissue was slightly higher 
than in s.c. adipose tissue (Figure 8b). The EC50 of isoproterenol in i.m. adipose tissue was 2.1 
nM. However, the cAMP accumulation was not dose-dependent in i.m. adipose tissue. Neither RH 
nor ZH affected cAMP production in s.c. and i.m. adipose tissue at low concentrations (10-8 to 10-





Figure 8. cAMP production in s.c. (a) and i.m. (b) adipose tissue in response to isoproterenol. 
Tissues were incubated with isoproterenol for 30 min at 37˚C. Data are expressed as mean values 
(n = 5). The results at each concentration of isoproterenol were fitted together by nonlinear 
regression.  
   
Isoproterenol, RH, and ZH-stimulated lipolysis in s.c. and i.m. adipose tissue 
To determine the effects isoproterenol, RH, and ZH on lipolysis, the release of glycerol 
and NEFA from s.c. and i.m. adipose tissues was measured. Isoproterenol increased glycerol 
concentrations in a dose-response manner in s.c. adipose tissue (EC50 = 5.1 µM), whereas it had 
no effect on glycerol release in i.m. adipose tissue (Figures 9a and 9b). RH and ZH increased 
glycerol concentrations in a dose-response manner in s.c. adipose tissue, but RH and ZH did not 
affect glycerol release in i.m. adipose tissue (Table 6). Likewise, isoproterenol increased glycerol 
release in s.c. adipose tissue, and isoproterenol also increased NEFA concentrations in a dose-
dependent manner in s.c. adipose tissue (EC50 = 0.18 µM) (Figure 9c). However, isoproterenol 
decreased the NEFA release in a dose-dependent manner in i.m. adipose tissue and (Figure 9d). 
Although RH and ZH increased NEFA release from s.c. adipose tissue at all concentrations 
compared to the basal level, NEFA release was not dose-dependent (Table 6). None of the ß-AR 





Figure 9. Glycerol and NEFA release in s.c. (a and c) and i.m. (b and d) adipose tissue in 
response to isoproterenol. Tissues were incubated with isoproterenol for 30 min at 37˚C (n = 5). 
Glycerol (a and b) and non-esterified fatty acid (NEFA) (c and d) released in tissue supernatant 
were determined. Data are expressed as mean values (n = 5). The results at each concentration of 




Table 6. Tissue cAMP, glycerol, and NEFA release stimulated by RH and ZH 
 RH1 ZH2 
 s.c. i.m. s.c. i.m. 
cAMP (pmol/ 100 mg tissue) 
Baseline 0.42 ± 0.06 0.64 ± 0.19 0.42 ± 0.06 0.64 ± 0.19 
10-8 0.39 ± 0.09 0.86 ± 0.22 0.76 ± 0.37 0.79 ± 0.30 
10-7 0.38 ± 0.08 0.76 ± 0.18 0.61 ± 0.27 0.51 ± 0.13 
10-6 0.44 ± 0.14 0.70 ± 0.18 0.62 ± 0.27 0.78 ± 0.39 
Glycerol (nmol/ 100 mg tissue) 
Baseline 50.0 ± 12.8 48.6 ± 10.3 50.0 ± 12.8 48.6 ± 10.3 
10-8 50.3 ± 7.60 52.4 ± 16.4 54.8 ± 8.00 67.4 ± 21.6 
10-7 52.6 ± 11.1 81.7 ± 25.5 59.3 ± 15.4 48.6 ± 13.7 
10-6 63.3 ± 9.20 42.6 ± 11.4 65.9 ± 12.6 46.0 ± 14.5 
NEFA (mol/ 100 mg tissue) 
Baseline 0.99 ± 0.40 0.65 ± 0.20 0.99 ± 0.40 0.65 ± 00.20 
10-8 1.10 ± 0.15 0.75 ± 0.21 1.06 ± 0.30 0.78 ± 0.28 
10-7 1.20 ± 0.21 1.18 ± 0.50 1.25 ± 0.31 0.91 ± 0.30 
10-6 1.06 ± 0.13 0.56 ± 0.13 1.17 ± 0.35 0.50 ± 0.16 
Values are means ± SEM; n = 6 steers. Means within treatment and tissue were not different (P > 
0.05). 1RH; Ractopamine Hydrochloride, 2ZH; Zilpaterol Hydrochloride. 
 
Lipolytic response to BRL-37344 and ExperiorTM for ß3-AR 
To determine if binding of ExperiorTM to ß3-AR might contribute to its lipolytic response, 
the selective ß3-AR agonist, BRL-37344, was used as a positive control to compare the effects on 
ExperiorTM in s.c. and i.m. adipose tissue. The pD2 value for Experior
TM was similar to the BRL-
37344 pD2 value in s.c. adipose tissue, whereas the pD2 value for Experior
TM was not applicable 
in i.m. adipose tissue (Table 7). No lipolytic responses for cAMP or NEFA were observed in s.c. 
adipose tissue for BRL-37344 or ExperiorTM (Figures 10a and 10c). Total cAMP production from 
i.m. adipose tissue was significantly less in BRL-37344-treated i.m. adipose tissue than in 
ExperiorTM-treated in i.m. adipose tissue at 10-6 and 10-5 M (P < 0.05), but no difference in NEFA 






Figure 10. cAMP and NEFA release in response to BRL-37344 and ExperiorTM in s.c. (a and 
c) and i.m. (b and d) adipose tissue. Tissues were incubated with either BRL-37344 or 




Table 7. Adipose tissue lipolytic sensitivity to ß-AR agonists 
       s.c.       i.m. 
ExperiorTM 7.40± 1.78 1N.A. 
BRL-37344 7.00 ± 3.27 N.A. 
Salbutamol 6.23 ± 0.35 4.59 ± 4.42 
Salbutamol + ExperiorTM 3.34 ± 0.59 *** 8.07 ± 4.90 
Salbutamol + ExperiorTM + L-748.337 4.04 ± 0.34 *** N.A. 
Dobutamine 5.50 ± 0.68 6.52 ± 1.23 
Dobutamine + ExperiorTM 6.44 ± 3.20 7.29 ± 1.44 
Dobutamine + ExperiorTM + L-748.337 5.87 ± 0.81 6.12 ± 1.70 
Values are means ± SEM of sensitivity (pD2) of adipose tissue = -log EC50; n = 12 cattle. pD2 was 
calculated from the individual concentration-response to agonists fitted together by nonlinear 
regression. EC50, half maximum effective response. 
1N.A., not applicable. It was not possible to 
calculate pD2 from the data.  






ExperiorTM as a ß1-and ß2-AR antagonist in s.c. adipose tissue 
We set the optimal concentrations of propranolol (50 µM), a non-selective ß-AR 
antagonist, and L-748,337 (10 µM), a selective ß3-AR antagonist based on preliminary tests, which 
caused depression of cAMP production in s.c. adipose tissue. Subcutaneous and i.m. adipose 
tissues were preincubated with either 50 µM propranolol or 10 µM L-748,337 for 30 min before 
adding ExperiorTM in a dose-response manner. The production of cAMP was reduced by 
ExperiorTM in a dose-response manner in s.c. adipose tissue pretreated with either 50 µM 
propranolol or 10 µM L-748,337 (Figures 11a and 11c). There was no effect of ExperiorTM on 
cAMP production in i.m adipose tissue preincubated with propranolol (Figure 11b). However, 
ExperiorTM depressed cAMP production in i.m. adipose tissue preincubated with L-748,337 







Figure 11. Depression of cAMP production in response to propranolol (a and b) and L-
748,337 (c and d) in s.c. and i.m. adipose tissue. Tissues were pre-incubated with 10 µM L-
748,337 or 50 µM propranolol, and then ExperiorTM was added for an additional 30 min. Data are 
expressed as mean values (n = 8). The results at each concentration of ExperiorTM were fitted 
together by nonlinear regression.    
 
Antagonism of ß1-and ß2-AR by ExperiorTM 
In s.c. adipose tissue, ExperiorTM blunted the production of cAMP in the presence of ß-AR 
antagonists, suggesting that ExperiorTM is also a ß-AR antagonist (Figure 11). To address this 
hypothesis, a selective ß1-AR agonist, dobutamine and a selective ß2-AR agonist, salbutamol, were 
used to stimulate cAMP production mediated directly by individual ß1-AR and ß2-AR subtypes. 
Dose-response curves for cAMP production induced by either dobutamine or salbutamol in s.c. 
and i.m. adipose tissue were indicated in Figure 12, and pD2 values are summarized in Table 7. 
Both salbutamol and dobutamine increased cAMP production in s.c. adipose tissue in a dose-
dependent manner (Figures 12a and 12c) but were without effect in i.m. adipose tissue (Figures 
12b and 12d). To investigate the antagonism of ExperiorTM to ß1- and ß2-AR, s.c. and i.m. adipose 
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tissues were pretreated with 1 µM ExperiorTM in the presence or absence of 10 µM L-74,337 before 
adding dobutamine or salbutamol. ExperiorTM and ExperiorTM plus 10 µM L-748,337 pre-
treatment to salbutamol significantly shifted the EC50 in s.c. adipose tissue (Figure 12a) (F (2, 99) 
= 19.21, P < 0.0001). Furthermore, ExperiorTM with or without L-748,337 significantly blunted 
cAMP production mediated by salbutamol in s.c. adipose tissue and the cAMP reduction was 
remarkable from 10-6 to 10-4 M of salbutamol (P < 0.05) (Figure 12a). There was no significant 
change in EC50 shift in response to dobutamine in the presence of Experior
TM and ExperiorTM plus 
L-748,337 in s.c. adipose tissue (P > 0.05). However, ExperiorTM plus L-748,337 significantly 
inhibited cAMP production mediated by dobutamine in s.c. adipose tissue (P < 0.05) (Figure 12c). 
Neither dobutamine nor salbutamol had any effect on cAMP production in i.m. adipose tissue. In 







 Figure 12. cAMP production in response to selective ß1- and ß2-AR agonists in s.c. (a and 
c) and i.m. adipose tissue (b and d). With 1 µM ExperiorTM or 1 µM ExperiorTM + 10 µM L-
748,337, salbutamol and dobutamine reduced cAMP production in s.c. and i.m. adipose tissues. 
Tissues were pre-incubated with 1 µM ExperiorTM or 1 µM ExperiorTM + 10 M L-748,337, and 
then salbutamol (a, b) or dobutamine (c, d) was added for an additional 30 min. The results of 
each individual concentration-response to salbutamol and dobutamine were fitted together by 
nonlinear regression. Data are expressed as means (n = 5). *P < 0.05.  
 
Discussion 
 In the present study, s.c. and i.m. adipose tissues were used to investigate the effects of 
different ß-AR agonists and antagonists along with the novel ß-AR ligand ExperiorTM on cAMP 
production induced by adenylyl cyclase/PKA/hormone sensitive lipase cascade. The results of this 
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study indicated that s.c. and i.m. adipose tissue have physiologically different responses to ß-AR 
agonists. Isoproterenol, RH and ZH stimulated glycerol and NEFA release from s.c. adipose tissue. 
In contrast, those ß-AR agonists were not effective in elevation of cAMP production or in release 
of glycerol or NEFA in i.m. adipose tissue. ExperiorTM significantly inhibited stimulation of cAMP 
production mediated by interaction of ß1-AR and ß2-AR and adenylyl cyclase in s.c. adipose tissue, 
whereas ExperiorTM did not have any effect in i.m. adipose tissue. 
ß-adrenergic receptors are G protein-coupled receptors, and three ß-AR subtypes (ß1-AR, 
ß2-AR, and ß3-AR) are expressed in most mammalian cells. The cellular proportion of each 
subtype present on the surface of membranes varies among tissues and across species. 
Furthermore, ß-AR subtypes, even in single cells, have different distributions among adipocytes 
(Seydoux et al., 1996). This suggests that each ß-AR subtype may be transcriptionally regulated 
to vary the proportion of their receptor subtypes on the cell surface. Early ADRB gene expression 
was reported in bovine oocytes and preimplantation embryos (Cikos et al., 2014). The first 
transcription gene of ADRB was the ß2-AR in the morula, and then all ADRB genes were expressed 
in the blastocyst, indicating that transcription of these genes begins early after embryonic genome 
activation. The current study confirmed ADRB expression in s.c. and i.m. adipose tissue from 
growing cattle and reported the distribution of ADRB in bovine i.m. adipose tissue for the first 
time. Both s.c. and i.m. adipose tissues expressed all three ß-AR, and the most abundant ADRB 
was the ADRB2. Interestingly, the ß1-AR and ß3-AR subtypes showed similar levels of gene 
expression in both s.c. and i.m. adipose tissues.  In the past, ADRB3 was believed to be expressed 
primarily on the surface of white and brown adipocytes in rodents (Strosberg, 1997). For two 
decades, the expression of ADRB3 had been identified and confirmed in various tissues of livestock 
spices. The ADRB3 gene is expressed in brown adipose tissue in cattle, s.c. adipose tissue in pigs, 
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most of the tissues of sheep, and s.c. adipose tissue, mammary gland, gastrointestinal tracts, and 
liver of dairy cattle (Casteilla et al., 1994; Pietri-Rouxel et al., 1995; McNeel and Mersmann, 1999; 
Inderwies et al., 2003; Meylan et al., 2004; Carron et al., 2005; Kobel et al., 2006; Sumner and 
McNamara, 2007; Wu et al., 2010). However, there were no reports for the identification ADRB3 
gene expression in s.c. and i.m. adipose tissue of beef cattle. Therefore, our findings are noteworthy 
in that we confirmed ADRB3 gene expression in adipose tissues of beef cattle for the first time.  
ß-Adrenergic agonists act as repartitioning agents that lead to the redirection of nutrients 
from lipid synthesis to protein synthesis, modulating animal growth in various species of mammals 
and birds, including cattle, pigs, poultry, and sheep (Jones et al., 1985; Moloney et al., 1990; 
Schiavetta et al., 1990; Smith et al., 1995). Oral administration of these ß-AR agonists (e.g., 
cimaterol, clenbuterol, L-644,969, and RH) increased muscle mass by increasing muscle protein 
synthesis and depressing adipose tissue accretion in livestock species by directly stimulating the 
triacylglycerol degradation and by inhibiting fatty acid and triacylglycerol synthesis in adipose 
tissue. The effects of ß-AR agonists begin with the stimulation of ß-AR through the G-coupled 
proteins to activate adenylyl cyclase which, in turn, stimulates production of cAMP. In current 
study, isoproterenol was chosen as the non-specific agonist for all ß-AR subtypes, to compare the 
effects of ZH and RH on cAMP-dependent lipolysis in response to ß-AR stimulation. After 30 min 
incubation, isoproterenol increased cAMP production and, consequently, induced increases in 
glycerol and NEFA release from s.c. adipose tissue in a dose-response manner. However, we 
prolonged the incubation time 60, 90, and 270 min, cAMP production was dramatically reduced 
(data not shown). This suggests that extended exposure to isoproterenol causes ß-AR to be 




 Although RH and ZH had no effect on cAMP production, the release of glycerol by RH 
and ZH in s.c. adipose tissue was increased. This suggest that the lipolytic response is controlled 
by even a very small range of cAMP levels (Allen and Quesenberry, 1988). The release of NEFA 
in response to RH and ZH was similar at individual concentrations, but the ZH effect was not 
significant. Activation of ß-AR stimulated by ß-AR agonists, including isoproterenol, cimaterol, 
clenbuterol, and RH in porcine adipose tissue increased the release of glycerol and NEFA (Peterla 
and Scanes, 1990). Meanwhile, oral administration of RH to pigs reduced fat accretion owing to 
suppression of the activity of lipogenic enzymes and, in turn, the depression of de novo fatty acid 
synthesis (Mills et al., 1990). Additionally, gene expression associated with lipid synthesis 
including sterol regulatory element binding protein-1(SREBP1), fatty acid synthase (FAS), and 
proliferator-activated receptor-2 (PPAR2) was also reduced in pigs by RH (Reiter et al., 2007; 
Halsey et al., 2011). Page et al. (2004) postulated that RH can trigger apoptosis in mouse adipose 
tissue (Page et al., 2004). Unfortunately, knowledge of altering lipogenic gene expression induced 
by ß-AR agonists is limited in cattle. Taken together, reduction in fat accretion induced by RH 
may be through increased lipolysis and depressed lipogenesis.  
Species have different expression and functional roles for ß-AR subtypes because of their 
potential redundancy and complexity in signaling responses, and the function of the ß3-AR is 
species-specific (Langin et al., 1991). The ß3-AR predominantly mediates the lipolytic response 
through selective ß3-AR agonists such as CL-316243 and BRL-37344 in rodents, rabbits, and dogs, 
whereas it is poorly responsive to ß3-AR agonists in humans, primates, guinea pigs, and pigs 
(Bousquet-Melou et al., 1994; Carpene et al., 1994; Langin et al., 1995; Mills, 2000). To date, 
there is no clear evidence for the existence of a functional ß3-AR in bovine adipose tissue from 
physiologically mature cattle. In our present study, we attempted to examine the presence of a 
 
 66 
functional ß3-AR in response to BRL-37344, a selective ß3-AR agonists, and Experior
TM, a newly 
synthesized, putative ß3-AR agonists in bovine adipose tissues. Both BRL-37344 and Experior
TM 
failed to stimulate cAMP production and NEFA release from s.c. and i.m. adipose tissues. Similar 
results were previously reported in porcine adipose tissue by Mills (2000), which tested ß3-
mediated lipolysis in response to BRL-37344 in porcine adipose tissue, in which BRL-37344 did 
not increase cAMP production or increase lipolysis (Mills, 2000). Our ADRB gene expression data 
showed that ß1-AR and ß3-AR were expressed similar levels in bovine s.c. and i.m. adipose tissues, 
which may propose a possibility of low Gs coupling with ß3-AR. Moreover, Soeder et al. (1999) 
demonstrated that ß3-AR can be constitutively coupled to Gs as well as Gi protein to control lipid 
metabolism (Soeder et al., 1999). This result raises another possibility as to why the concentrations 
of cAMP or NEFA produced by ß3-AR activation remained unchanged with increasing in ß3-AR 
agonist concentrations. In addition, ExperiorTM exhibited similar sensitivity (pD2) to adipose tissue 
as BRL-37344 in both adipose tissues, suggesting that ExperiorTM may function as a ß3-AR agonist 
in rodents or rabbits to same extent of BRL-37344. Taken together, ß3-AR may not be functional 
in bovine adipose tissue and the tissue distribution of ß3-AR in cattle is very different from that of 
rodents. 
Individual ß1-AR or ß2-AR subtypes have different abilities to evoke the cAMP production. 
Dobutamine, a ß1-AR agonist, modestly increased cAMP production, while salbutamol, a ß2-AR 
agonist, strongly evoked cAMP production in s.c. adipose tissue, suggesting that ß2-AR is the 
primary regulator of lipolysis in cattle, and that the ß1-AR has a lesser function in lipolysis.  
To investigate the antagonism of ExperiorTM, we co-incubated ExperiorTM with tissues pre-
treated propranolol, a non-selective ß-AR antagonist. cAMP production was depressed strongly 
by increasing ExperiorTM concentrations. Further, following pre-treatment with ExperiorTM, 
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ExperiorTM inhibited the ability for salbutamol and dobutamine to increase cAMP accumulation. 
This supports the concept that ExperiorTM functions better as a selective antagonist for ß1-AR or 
ß2-AR than as a ß3-AR agonist in bovine adipose tissue. Backer et al. (2003) proposed the existence 
of two separate binding sites of the human ß1-AR: 1) one for classic agonists and ß-antagonists 
and 2) the other for another agonist (i.e., CGP 12177) (Baker et al., 2003). CGP 12177 is an agonist 
that is relatively resistant to inhibition by propranolol and CGP 20712A (Konkar et al., 2000). The 
results of the current study demonstrated that dobutamine and salbutamol had agonistic effects on 
individual ß1-AR and ß2-AR, respectively, and also depressed cAMP production by Experior
TM at 
higher concentrations of dobutamine and salbutamol. Furthermore, the combination of propranolol 
plus ExperiorTM decreased cAMP production. This suggests that bovine ß1-AR or ß2-AR may have 
two separate binding sites, and each ß-AR agonist and ExperiorTM may act on different binding 
sites in bovine adipose tissue.  
In the current study, i.m. adipose tissue did not show a reproducible lipolytic response to 
ß-AR agonists, although cAMP production was greater in i.m. adipose tissue than in s.c. adipose 
tissue for all experiments. Adipocyte diameter and volume in i.m. adipose tissue are less than in 
s.c. adipose tissue (Smith and Crouse, 1984; Miller et al., 1989). Subcutaneous adipose tissue may 
develop initially as brown adipose tissue, subsequently dedifferentiating and redifferentiating to 
white adipose tissue (Landis et al., 2002). The current study demonstrated that the levels of gene 
expression of ß-AR were much lower in i.m. adipose tissue than that of s.c. adipose tissue, which 
indicates small amounts of ß-AR populations in i.m. adipose tissue. Therefore, i.m. adipose tissue 
apparently would be less responsive to lipolysis induced by synthetic or parasympathetic 
stimulation than s.c. adipose tissue.   
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In conclusion, our results indicate the potential specificity of adipose tissue in the 
expression of particular ß-AR subtypes during cattle growth and different physiological responses 
of ß-AR subtypes to ß-AR agonists administration in s.c. and i.m. adipose tissue. We also 
investigated cAMP accumulation and lipolysis mediated by the interaction of ß-AR and ß-AR 
agonist, resulting in increased lipolysis in s.c. adipose tissue.  ExperiorTM, a novel ß-AR agonist, 
may be both a ß3-AR agonist and a ß1-AR and ß2-AR antagonist.  These unique combinations of 
agonistic and antagonistic effects may have confounding impacts on lipolysis and muscle 







ASSESSMENT OF ANTAGONISTIC EFFECTS ON 1/2-ADRENERGIC RECEPTORS 
USING A NOVEL -AR LIGAND IN BOVINE ADIPOCYTES 
 
Introduction 
The adrenergic receptors ( and ß) are a class of G protein-coupled receptors, and three ß-
AR subtypes have been identified in the most mammalian tissues, ß1-AR, ß2-AR, and ß3-AR 
(Strosberg, 1997). The proportions of ß-AR subtypes in adipose tissue varies with species. For 
example, ß2-AR is the most predominant subtype in bovine adipose tissue and human adipose 
tissue, ß1-AR is the primary subtype in porcine adipose tissue, and ß3-AR is the most abundant 
subtype in rodent adipose tissue (Sillence and Matthews, 1994; McNeel and Mersmann, 1999; 
Johnson et al., 2014). These ß-AR subtypes either stimulate or inhibit the physiological response 
in binding to ß-agonists (ß-AA) or ß-antagonists (Hershberger, 1994; Woodcock, 2007; Lynch and 
Ryall, 2008), which the stimulation of ß-AR by ß-AA signals through G-protein Gs to activate 
the adenylate cyclase (AC)-cAMP-protein kinase A (PKA) signaling cascade (Mersmann, 1998; 
Wallukat, 2002).  
Adipose tissue is uniquely sensitive to ß-AA. The activation of ß-AR by  ß-AA promotes 
lipolysis of triglyceride in lipid droplets, thereby releasing mobilized fatty acids and other 
precursors derived from stored triglyceride, which are used for energy generation (Barbosa et al., 
2015). The lipolysis is known to be induced by ß1-AR and ß2-AR in mammals except for rodents, 
as the ß3-AR in rodent white and brown adipocytes mainly mediates lipolysis. Nevertheless, 
lipolysis mediated by ß-AR has also been reported in various mammals, but the effects were low 
(Bousquet-Melou et al., 1994). For instance, ß3-AR agonists induced lipolysis in white adipocytes 
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from marmosets, dogs, and rats, while they were ineffective in stimulating lipolysis in white 
adipocytes from baboons, macaques and humans. Lipolysis induced by ß3-AR on bovine white 
adipose tissue remain unclear. In addition, specificity between synthetic ß-AA and ß-AR reveals 
species-specific differences. Ractopamine and clenbuterol are partial ß-agonists in porcine 
adipocytes (Liu et al., 1989), and they are reacted as antagonists in porcine adipocytes under certain 
conditions (Liu and Mills, 1989). BRL- 37,344 and CL-316,243, selective ß3-agonists, had full 
agonistic effects in rat and dog white adipocytes, whereas another ß3-agonists such as CGP-12,177 
and SR-56,811A were partial agonists in rat and dog white adipocytes (Bousquet-Melou et al., 
1994).  
ß-Adrenergic agonists traditionally have been used for the treatment of chronic bronchitis, 
chronic obstructive pulmonary disease, asthma, uterine relaxants, and cardiac irregularities for 
more than 30 year (Barnes, 1999). Interestingly, some ß-AA (e.g., zilpaterol, ractopamine, 
cimaterol, terbutaline, matuberol and salbutamol) in livestock industry revealed repartitioning 
effects, which promotes muscle hypertrophy through increase in muscle protein synthesis and 
decrease in adipose tissue mass by stimulation through triacylglycerol degradation and inhibition 
of their synthesis and fatty acid synthesis (Emery et al., 1984; Jones et al., 1985; Moloney et al., 
1990; Schiavetta et al., 1990; Smith et al., 1995). Therefore, these ß-AA contribute to improvement 
of feed utilization, lean growth rate, and carcass lean percentage in cattle, pigs, poultry and sheep. 
At present, most ß-AR agonists commercially available, such as zilpaterol, ractopamine, cimaterol, 
terbutaline, matuberol and salbutamol target ß1-AR and ß2-AR. Recently, a new ß-AR modulator, 
lubabegon fumarate (as known as ExperiorTM) has been synthesized by Elanco Animal Health. 
Preliminary data indicated that ExperiorTM acted as ß3-AR agonist and a ß1-AR and ß2-AR 
antagonist in Chinese hamster ovary cells (M. E. Spurlock, unpublished data). Our previous study 
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(chapter 4) revealed that ExperiorTM showed strong antagonistic effects on ß1-AR and ß2-AR in 
bovine subcutaneous (s.c.) adipose tissue explant culture. Based on these observations, we used 
primary bovine s.c. and intramuscular (i.m.) adipocytes to investigate the mechanisms regulating 
ß-AR stimulation mediated by ExperiorTM. 
 
Materials and Methods 
 
Materials 
Lubabegon fumarate (ExperiorTM) was provided by Elanco Animal Health (Elanco Animal 
Health, Indianapolis, IN). Other drugs and reagents were purchased from the following companies: 
dobutamine, salbutamol, propranolol, insulin, dexamethasone, gentamicin, Glycerol Assay Kit, 
DNAseI, bovine serum albumin (BSA), phenymethylsulfony fluoride (PMSF), and phosphatase 
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO); troglitazone, rosiglitazone, ciglitazone, 3-
isobutyl-1-methylxanthine (IBMX), and forskolin (Cayman Chemical, Ann Arbor, MI); Cell 
Counting kit-8 (Dojindo, Rockville, MD); Cyclic AMP XP® Assay Kit, Hormone Sensitive Lipase 
(HSL) antibody and phospho-HSL (Ser563) antibody  (Cell Signaling Technology, Danvers, MA); 
antibiotic-antimycotic, Dulbecco’s modified Eagle’s Medium, nutrient mixture Ham’s F12 
(DMEM/F12), Dulbecco’s phosphate-buffer saline (DPBS), collagenase II, gentamicin, 
amphotericin B, Protein Kinase A Colorimetric Activity Kit, Pierce BCA Protein Assay Kit, and 
protease inhibitor (Thermo Fisher Scientific, Waltham, MA); nonesterified fatty acid (NEFA) kit 
(Wako Life Sciences, Inc., Mountain View, CA); qScriptTM cDNA synthesis kit and Perfecta® 
SYBR® Green fastmix® (Quanta Biosciences, Gaithersburg, MD); HiBind® RNA mini column 
(Omega Bio-tek, Inc., Norcross, GA); polyvinylidene fluoride (PVDF) membrane (GE Healthcare 
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Bio-Sciences, Pittsburgh, PA); anti-ß-actin (Santa Cruz Biotechnology, Inc., Dallas, TX); 
horseradish peroxidase-conjugated rabbit anti-goat IgG (Abcam, Cambridge, MA). 
 
Bovine adipose tissue sampling at slaughter 
Angus crossed bred steers were fed a standard, corn-based finishing diet at the Texas A&M 
University McGregor Research Center, McGregor, TX, and then transported approximately 190 
km to the Texas A&M Rosenthal Meat Science and Technology Center, College Station, TX. 
Cattle were stunned using a captive bolt followed by exsanguination. The longissimus muscle 
(LM) and overlying s.c. adipose tissue from the 8th to 10th thoracic region was removed by cutting 
through the hide immediately lateral to the spinal process. The muscle was immediately 
transported to the laboratory in pre-warmed DPBS with 3% antibiotic-antimycotic within 30 min. 
 
Primary preadipocyte isolation from bovine adipose tissues 
Fresh LM and overlying s.c. adipose tissue were rinsed with pre-warmed DPBS containing 
1% antibiotic-antimycotic to remove blood clots. Subcutaneous adipose tissue and i.m. adipose 
tissues (dissected fresh from the LM muscle) were minced into small pieces using surgical scissors 
and incubated in pre-warmed digestion buffer containing DMEM/F12 (1:1 vol/vol), 0.15% 
collagenase II, and 1% BSA (essentially fatty acid free) for 45 min at 37°C in a shaking incubator. 
Following incubation, the digest was filtered through a 100-m nylon mesh to eliminate 
undigested adipose tissues, mature adipocytes and large cell aggregates. The filtered stromal 
vascular fractions were centrifuged at 1,500 rpm for 10 min at room temperature, and then were 
incubated in erythrocyte lysis buffer for additional 5 min at room temperature to lyse red blood 
cells. The suspension was centrifuged at 1,500 rpm for 10 min, and resuspended in fresh growth 
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medium (DMEM/F12, 10% FBS and 1% antibiotic-antimycotic). The preadipocytes were counted 
and directly cultured at 37°C in a humidified incubator with 5% CO2 or were frozen in lipid 
nitrogen until further use. 
 
Cell viability assay 
Subcutaneous preadipocytes were seeded at a density of 5×103 cells/well in 96-well 
microplates. Cells were incubated with or without dobutamine, salbutamol, or ExperiorTM for 
varying time periods and with various concentrations. Viabilities were evaluated by the cell 
counting kit-8 (CCK-8) according to the manufacturer’s instructions. Eight wells were set in each 
group. Following treatment, 10 L of CCK-8 was added into each well, and then the cells were 
incubated for additional 2 h in an incubator at 37°C. The absorbance of the formazan product was 
measured at 450 nm using an Epoch microplate reader (Biotek Instruments, Winooski, VT). 
 
Preadipocytes differentiation 
Subcutaneous and i.m. preadipocytes were cultured in normal growth media until 80% 
confluent. Cells were differentiated for 14 d into mature adipocytes in DMEM/F12 containing 
2% FBS, 1 μM dexamethasone, 20 μg/mL insulin, 0.5 mM IBMX, 50 µg /mL gentamicin, 2.5 
µg/mL amphotericin B, 1% antibiotic-antimycotic supplemented with PPAR agonists (10 μM 
troglitazone, 10 μM ciglitazone, and 1 μM rosiglitazone) for the first 8 d. From d 8 to d 14, 
maintenance medium supplemented only with 20 μg/mL insulin and 1 μM rosiglitazone was 
used. The medium was replaced every 48 h. Morphologic changes of the s.c. and i.m. adipocytes 




Production of cAMP 
The level of cAMP production in s.c. and i.m. adipocytes was determined by using the 
Cyclic AMP XP® Assay Kit according to the manufacturer’s instructions. Briefly, s.c and i.m 
preadipocytes were seeded at a density of 2×104 cells/well in 24-well microplates. At d 14 of 
differentiation, s.c. and i.m. adipocytes were starved for 1 h in DMEM/F12 containing 0.5% BSA, 
0.5 mM IBMX, 10 μM forskolin and 1% antibiotic-antimycotic at 37°C. After starvation, the cells 
were pre-stimulated in the presence or absence of either 1 μM ExperiorTM or 10 μM propranolol 
for 5 min. Following 5 min, the cells were stimulated with 10 μM dobutamine, 10 μM salbutamol, 
or 1 μM ExperiorTM for 15 min. The cells in 24-well plates were lysed in 200 μL of cell lysis buffer 
provided by the kit with 1 mM PMSF and 10 μL/ mL of protease inhibitor. The cell lysate was 
centrifuged at 14,000 x g for 10 min at 4 °C to remove cell debris. Fifty microliters of cell lysates 
from s.c. and i.m. adipocytes or standards were co-incubated in 96-well plates with the horseradish 
peroxidase (HRP)-linked cAMP substrate coated onto an immobilized rabbit monoclonal cAMP 
antibody at room temperature for 3 h on a horizontal orbital plate shaker. Next, 100 μL of the TMB 
substrate were added to each well and incubated at room temperature for 30 minutes. Afterward, 
100 μL of stop solution was added to each well. After the reaction, color development was 
measured at 450 nm using an Epoch microplate reader. A standard curve was generated by a four-
parameter logistic regression, and cAMP concentrations were calculated using GrapPad Prism 6.04 
software (GraphPad Software Inc., San Diego, CA). Protein concentrations were determined by 






Protein Kinase A activity  
Protein Kinase A activity was measured using PKA Colorimetric Activity Kit following 
manufacturer’s protocol. Briefly, cells in 24-well plates were lysed in 200 μL of activated cell lysis 
buffer provided by the kit with 1 mM PMSF, 1 μL/mL protease inhibitor and 1 μL/mL phosphatase 
inhibitor cocktail and incubated for 30 min on ice with occasional vortexing. The lysates were 
centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant fraction was used as substrates for 
the PKA enzymes. All supernatant fractions were diluted 1:1 in kinase assay buffer provided by 
the kit, adding 1 mM PMSF and 0.5 μL/mL protease inhibitor. Forty microliters of samples or 
standards and 10 μL of ATP were co-incubated in 96-well plates at 30°C for 90 min on a horizontal 
orbital plate shaker. The wells then were aspirated and washed 4 times with wash buffer. Twenty-
five microliters of rabbit phospho PKA substrate antibody and 25 μL of secondary goat anti-rabbit 
IgG-HRP were co-incubated at room temperature for 60 min with shaking. Next, 100 μL of the 
TMB substrate were added to each well and incubated at room temperature for 30 min. Afterward, 
50 μL of stop solution was added to each well. Color development was measured at 450 nm using 
an Epoch microplate reader. A standard curve was generated by a four-parameter logistic 
regression, and the PKA activity was calculated using GrapPad Prism 6.04 software. 
 
Lipolysis assay 
To test lipolysis, s.c and i.m preadipocytes were seeded at a density of 2×104 cells/well in 
24-well microplates. At day 14 of differentiation, s.c. and i.m. adipocytes were starved for 2 h in 
DMEM/F12 containing 0.5% BSA, 0.5 mM IBMX, and 1% antibiotic-antimycotic at 37°C. 
Following starvation, the cells were pre-stimulated in the presence or absence of either 1 μM 
ExperiorTM or 10 μM propranolol for 30 min. After 30 min, the cells were stimulated with 10 μM 
 
 76 
dobutamine, 10 μM salbutamol or 1 μM ExperiorTM for 6 h. After 6 h, media were harvested for 
measuring concentration of glycerol and NEFA. The cells were harvested for protein 
quantification. Lipolysis was measured with a glycerol assay kit and a NEFA kit according to the 
manufacturer’s procedures. In brief, to determine glycerol released from cells, 10 µL of media was 
reacted with 100 μL glycerol reaction reagent for 20 min at room temperature and the absorbance 
was measured at 570 nm. The glycerol standard was used to generate a calibration curve. To 
analyze the level of NEFA released from the cells, 10 μL of media plus 200 μL of the first reagent 
was incubated for 5 min at 37°C, then 100 L of the second reagent was incubated for another 5 
min at 37°C. The absorbance was read at 550 nm. Oleic acid was used to plot a standard curve and 
to calculate concentration of NEFA in the media. Glycerol and NEFA release were normalized to 
cellular protein content. 
 
Quantitative real-time RT-qPCR 
Subcutaneous and i.m preadipocytes were seeded at a density of 5×105 cells in T-25 flasks. 
At d 14 of differentiation, the cells were stimulated with 10 μM dobutamine, 10 μM salbutamol, 1 
μM ExperiorTM, dobutamine plus ExperiorTM, and salbutamol plus ExperiorTM for 3 d in 
DMEM/F12 containing 2% FBS, and 1% antibiotic-antimycotic at 37°C. Total RAN was isolated 
from s.c. and i.m. cells using HiBind® RNA mini columns followed by DNAseI treatment. Total 
RNA was quantified on the NanoDropTM 2000 Spectrophotometer (Thermo Fisher Scientific, 
Waltham, MA) and reverse transcription was performed with the qScriptTM cDNA synthesis kit. 
The gene expressions of lipid metabolism related genes in s.c. and i.m. cells were analyzed in a 
CFX384TM Real-Time System (Bio-rad, Hercules, CA) using the Perfecta® SYBR® Green 
fastmix® kit. The different efficacy of cDNA synthesis between samples was normalized with 
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three reference genes (ribosomal protein 9 (RSP9), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), and succinate dehydrogenase (SDHA)).  The relative expression of mRNA was 
determined by the cycle threshold (CT) deviation of an unknown sample vs geometric mean of 
three reference genes and data were presented as either 2-ΔCT or 2-ΔΔCT. The primers used in this 


































































































To measure HSL activity, at d 14 of differentiation, s.c. and i.m. adipocytes in T-25 flasks 
were starved for 1 h in DMEM/F12 containing 2% FBS, 0.5mM IBMX, and 1% antibiotic-
antimycotic at 37°C. After starvation, the cells were pre-stimulated in the presence or absence of 
1 μM ExperiorTM for 30 min. After 30 min of pre-treatment, the cells were stimulated with 10 μM 
dobutamine, 10 μM salbutamol or 1 μM ExperiorTM for 6 h, then cells were harvested for protein 
extraction. Protein concentrations in samples were quantified using Pierce™ BCA Protein Assay 
Kit.  Total protein (10 µg) was separated on a 10% SDS-PAGE gel at constant current.  Proteins 
in the gel were transferred onto a PVDF membrane using a Trans-blot® SD Semi-dry Transfer 
Cell (Bio-Rad, Hercules, CA) for 1 h. The membrane was immediately blocked with ether a 5% 
non-fat milk solution or 5% BSA (for phosphor-protein detection) at room temperature for 1 h. 
The membrane was then incubated overnight at 4°C with anti-HSL (1:500), phospho-HSL 
(Ser563) (1:500), anti-ß-actin (1:10,000). The membranes were incubated with horseradish 
peroxidase-conjugated rabbit anti-goat IgG (1:1,000) for 2 h at room temperature. The proteins on 
the membrane were visualized using an enhanced chemiluminescence detection kit (Bio-Rad, 
Hercules, CA). Bands were quantified using Image Studio Lite version 5.2 software (LI-COR 
Biotechnology, Lincoln, NE) and protein levels were normalized to ß-actin on the same membrane. 
 
Statistical analysis 
All the experiments were performed in triplicates with at least three independent runs. The 
data are expressed as means ± SEM. Statistical analyses were tested either the two-sided, unpaired 
student’s t-test or one-way analysis of variation (ANOVA) with either LSMeans Student’s t or 
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Dunett’s test using JMP Pro 13 software (SAS Institute Inc., Cary, NC). A P-value < 0.05 was 
considered significant.  
 
Results 
Induction of differentiation in bovine s.c. and i.m. preadipocyte and validation of concomitant 
gene expression 
In this study, we have successfully induced adipogenic differentiation in bovine primary 
cultured preadipocytes (Figure 13). Before inducing adipogenic differentiation, s.c. and i.m. 
preadipocytes were phenotypically fibroblasts-like morphologies (Figures 13a and 13b). With the 
introduction of differentiation media, small lipid droplets were starting to become visible under a 
light microscope from d 3. Exposure to the differentiation media for 8 d led to an enhanced 
adipogenic differentiation of s.c and i.m. preadipocytes. For six additional days, cultured in 
maintenance medium supplemented only with 20 μg/mL insulin and 1 μM rosiglitazone, these s.c. 
and i.m. preadipocytes had further formations of medium to large lipid droplets (Figures 13c and 
13d).   
To further validate the adipogenic differentiation of s.c. and i.m preadipocytes, 
differentiation was confirmed by genes expressed in the commitment (C/EBPα and PPARγ) and 
terminal phase (FABP4) of adipogenesis through RT-qPCR. There were significant increases in 
expression of adipogenic genes in differentiated s.c. and i.m adipocytes (P < 0.05) (Figures 13e 
and 13f). The expression of C/EBP and PPAR was 2- and 6-fold higher expression in 
differentiated s.c. adipocytes than in s.c. preadipocytes, respectively (Figure 13e). Unlike s.c 
adipocytes, the expression of C/EBP was 1.7-fold upregulated, but the expression of PPAR was 
not different in differentiated i.m adipocytes compared with i.m. preadipocytes (Figure 13f). The 
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FABP4 gene was highly expressed in both s.c. adipocytes (50-fold) and i.m. adipocytes (14-fold) 
compared to s.c. and i.m. preadipocytes, respectively even though levels of FABP4 expression in 
i.m. adipocytes were less than in s.c. adipocytes.  
 
 
Figure 13. Morphological changes after induction of differentiation in bovine s.c. and i.m. 
preadipocyte and validation of concomitant gene expression. (a) s.c. preadipocytes. (b) i.m. 
preadipocytes. (c) Differentiated s.c. adipocytes. (d) Differentiated i.m. adipocytes. (e) relative 
gene expression levels in s.c. adipocytes. (f) relative gene expression in i.m. adipocytes. Data are 
expressed as means ± SEM (n = 5). *P < 0.05, **P < 0.01, ***P <0.001, differentiated 




ß-adrenergic receptor genes (ADRB) profiling in primary s.c. and i.m. adipocytes 
We have successfully detected all three ß-adrenergic receptor (ADRB) genes in both 
preadipocytes and differentiated adipocytes (Figures 14a and 14b). All ADRB genes were observed 
at least 2.5 times higher in differentiated s.c. adipocytes than in s.c. preadipocytes (P < 0.05). The 
predominant ß-AR subtype was ß2-AR in s.c. preadipocytes, whereas the proportions of ADRB 
genes were not different in s.c. adipocytes upon differentiation (Figure 14a). In contrast, the 
expressions of ADRB genes did not differ in i.m. adipocytes compared to preadipocytes except for 
ß2-AR. The ADRB2 gene was highly expressed in i.m preadipocytes (P < 0.05). After induction of 
differentiation, the expression of ADRB2 gene was significantly depressed in i.m. adipocytes 
(Figure 14b).   
 
 
Figure 14. Investigation of ß-adrenergic receptor subtypes by RT-qPCR in bovine primary 
preadipocytes and differentiated adipocytes. (a) ß-AR gene profiling in s.c. preadipocytes and 
differentiated adipocytes. (b) ß-AR gene profiling in i.m. preadipocytes and differentiated 
adipocytes. Data are expressed as means ± SEM (n = 5). *P < 0.05, ***P < 0.001, differentiated 
adipocytes vs preadipocytes. abMeans across each ADRB receptors within each preadipocyte 




Changes in s.c. preadipocytes proliferation after exposure to ß-AR agonists 
We have evaluated the proliferation of s.c. preadipocytes to select optimal concentrations 
of ß-AR agonists for further studies. The cells were treated with various concentrations of 
dobutamine, salbutamol, and ExperiorTM for various time points, and cell proliferation was 
measured by cell counting kit-8 (CCK-8). The CCK-8 assay indicated that individual ß-AR 
agonists showed different proliferative influences on s.c preadipocytes, especially at high 
concentrations after 1h incubation of these ß-AA (Figure 15). Following 1 h incubation, the 
treatment of dobutamine, a selective ß1-AA, promoted the proliferation of preadipocytes by 59% 
and 200% at concentrations of 10 µM and 100 µM, respectively (P < 0.05) (Figure 15a). However, 
the exposure of various concentrations of salbutamol, a selective ß2-AA, did not alter the 
proliferation of preadipocytes (Figure 15d). In contrast, the treatment of ExperiorTM, a novel ß-AR 
modulator, inhibited the proliferation of preadipocytes by 46% and 63% at concentrations of 10 
µM and 100 µM, respectively (P < 0.05) (Figure 15g). Based on these results, we decided to 
prolong the exposure time up to 6 h for dobutamine and salbutamol. Furthermore, we selected 1 
µM ExperiorTM to evaluate proliferation of preadipocytes for extended time points (3 to 72 h) and 
10 µM ExperiorTM for testing toxic effect on preadipocytes. Dobutamine treatment promoted cell 
proliferation up to 126% and 293% at concentrations of 10 µM and 100 µM, respectively, by 
increase in time (P < 0.05) (Figures 15b and 15c). In addition, 1 µM dobutamine also significantly 
increased cell proliferation by 67% at 6 h incubation (Figure 15c). In contrast, no changes in the 
proliferation of the preadipocytes were observed after treatment with serial concentration ranges 
of salbutamol until 3 h (Figure 15e). However, salbutamol promoted at least 50% cell proliferation 
at all concentrations at 6 h incubation (P < 0.05) (Figure 15f). There was no change in cell 
proliferation treated with 1 µM ExperiorTM until 24 h but a significant increase in cell proliferation 
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after 48 h (P < 0.05) (Figure 15h). ExperiorTM (10 µM) reduced proliferation of preadipocytes by 
21% after 5 min incubation. After 45 min, the rate of proliferation of preadipocytes was reduced 
by 38% (Figure 15i). Taken together, we selected 10 µM dobutamine and salbutamol and 1 µM 
ExperiorTM for further studies. 
 
Figure 15. Cell viability after treatment with dobutamine, salbutamol, or ExperiorTM in 
bovine preadipocytes. Dose responses for cell viability after exposure to dobutamine at 1 h (a), 3 
h (b), and 6 h (c). Dose responses for cell viability after exposure to salbutamol at1 h (d), 3 h (e), 
and 6 h (f). Dose responses for cell viability after exposure to ExperiorTM (g). Cell viability after 
exposure to 1 µM ExperiorTM at different time points (f). Cell viability after exposure to 10 µM 
ExperiorTM at different time points (i). Data are expressed as means ± SEM (n = 4). *P < 0.05, **P 
< 0.01, ***P <0.001, ****P < 0.0001, vs control (either MeOH or DMSO). 
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ExperiorTM as a ß1-and ß2-AR antagonist in s.c and i.m. adipocytes  
Our previous study demonstrated that ExperiorTM inhibited the activity of AC in bovine 
s.c. adipose tissue. Based on these results, we hypothesized that ExperiorTM acts as a ß-AR 
antagonist. To address this hypothesis, we used a selective ß1-AA, dobutamine, and a selective ß2-
AA, salbutamol, to stimulate individual ß1-AR and ß2-AR in s.c. and i.m. adipocytes. As an index 
of activation of ß1-AR and ß2-AR, we estimated the activity of AC by measuring cAMP 
production. We treated 10 µM dobutamine, 10 µM salbutamol, and 1 µM ExperiorTM for 15 min 
in s.c. and i.m adipocytes that were pre-starved for 1 h in starvation media supplemented with 0.5 
mM IBMX and 10  µM foreskin at d 14 of differentiation. The activity of AC was significantly 
increased by dobutamine treatment (P < 0.05), somewhat increased by salbutamol treatment, but 
was not altered by ExperiorTM treatment as compared to control s.c adipocytes (Figure 16a). In 
contrast, AC activity was not changed by these ß-AA and ExperiorTM treatments in i.m. adipocytes 
(Figure 17a). To investigate the antagonism of ExperiorTM against ß1-AR and ß2-AR in s.c. and 
i.m. adipocytes, the cells were pretreated with 1 µM ExperiorTM for 5 min before adding 
dobutamine or salbutamol. In addition, as a positive control, 10 µM propranolol, a non-selective 
ß-AR antagonist was prior to assess dobutamine or salbutamol. Following pre-treatment with 
either ExperiorTM or propranolol, they strongly blocked the potency for dobutamine and 
salbutamol to stimulate ß1-AR and ß2-AR, resulting in less stimulation of AC, and thereby less 
cAMP production than either dobutamine or salbutamol alone in s.c. adipocytes produced cAMP 
(P < 0.05) (Figures 16b and 16c). In contrast, dobutamine did not activate ß1-AR in i.m. adipocytes 
(Figure 17a), and neither ExperiorTM nor propranolol treatment also exhibited antagonistic effects 
on ß1-AR (Figure 17b). However, Experior
TM effectively blunted the stimulation of ß2-AR in i.m. 
adipocytes (P < 0.05) (Figure 17c).  
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  The results on PKA activity were similar to that of AC activity in s.c. and i.m. adipocytes. 
PKA activity was significantly increased in dobutamine treatment (P < 0.05), somewhat increased 
in salbutamol treatment, but was not different from control with ExperiorTM treatment in s.c 
adipocytes (Figure 16d). There were no differences of PKA activity among treatments in i.m. 
adipocytes (Figure 17d). The activity of PKA was strongly reduced with co-treatment of 
ExperiorTM or propranolol with either dobutamine or salbutamol when compared to treatments of 
dobutamine or salbutamol alone in s.c. adipocytes (P < 0.05) (Figures 16e and 16f). However, 
PKA was not activated by either dobutamine alone or combined treatments in i.m. adipocytes 
(Figure 17e). In salbutamol treatment group, PKA activity tended to be reduced by ExperiorTM and 










Figure 16.  The effect of dobutamine, salbutamol, and ExperiorTM on adenylyl cyclase and 
PKA activity in differentiated s.c. adipocytes. At d 14 of differentiation, s.c. adipocytes were 
starved for 1 h in DMEM/F12 containing 0.5% BSA, 0.5 mM IBMX, 10 µM forskolin and 1% 
antibiotic-antimycotic at 37°C. After starvation, cells were pre-stimulated in the presence or 
absence of either 1 µM ExperiorTM or 10 µM propranolol for 5 min. Following 5 min, the cells 
were stimulated with 10 µM dobutamine, 10 µM salbutamol, or 1 µM ExperiorTM for 15 min. (a-
c) Adenylyl cyclase activity in the presence or absence of either 1 µM ExperiorTM or 10 µM 
propranolol. (d-f) PKA activity in the presence or absence of ExperiorTM or propranolol. Data are 
expressed as means ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. C, 
basal; E, ExperiorTM; D, dobutamine; S, salbutamol; P, propranolol; DE, dobutamine plus pre-
treated with ExperiorTM; DP, dobutamine plus pre-treated with propranolol; SE, salbutamol plus 






Figure 17. The effect of dobutamine, salbutamol, and ExperiorTM on adenylyl cyclase and 
PKA activity in differentiated i.m. adipocytes. At d 14 of differentiation, s.c. adipocytes were 
starved for 1 h in DMEM/F12 containing 0.5% BSA, 0.5 mM IBMX, 10 µM forskolin and 1% 
antibiotic-antimycotic at 37°C. After starvation, cells were pre-stimulated in the presence or 
absence of either 1 µM ExperiorTM or 10 µM propranolol for 5 min. Following 5 min, the cells 
were stimulated with 10 µM dobutamine, 10 µM salbutamol, or 1 µM ExperiorTM for 15 min. (a-
c) Adenylyl cyclase activity in the presence or absence of either 1 µM ExperiorTM or 10 µM 
propranolol. (d-f) PKA activity in the presence or absence of ExperiorTM or propranolol.  Data are 
expressed as means ± SEM (n = 3). **P < 0.01. C, basal; E, ExperiorTM; D, dobutamine; S, 
salbutamol; P, propranolol; DE, dobutamine plus pre-treated with ExperiorTM; DP, dobutamine 
plus pre-treated with propranolol; SE, salbutamol plus pre-treated with ExperiorTM; SP, salbutamol 
plus pre-treated with propranolol.  
 
 89 
The effects of ExperiorTM on lipolysis in s.c. and i.m. adipocytes 
Previous results revealed that ExperiorTM repressed the ß-AR/AC/PKA signaling cascades 
in s.c and i.m adipocytes.  Based on these results, we hypothesized that binding of ExperiorTM to 
ß1-AR and ß2-AR would inhibit lipolysis in s.c and i.m adipocytes. To test this hypothesis, we 
measured the levels of glycerol and NEFA release from s.c. and i.m. adipocytes as an index of 
lipolysis. The cells were treated with 10 µM dobutamine, 10 µM salbutamol, and 1 µM ExperiorTM 
for 6 h after 2 h in starvation media supplemented with 0.5 mM IBMX at d 14 of differentiation. 
Glycerol release was increased by dobutamine (P < 0.05) but not altered by ExperiorTM and 
salbutamol treatments as compared to control s.c adipocytes (Figure 18a). Glycerol release was 
not altered by dobutamine, salbutamol, or ExperiorTM in i.m. adipocytes (Figure 19a). To test the 
effects of ExperiorTM on lipases in s.c. and i.m. adipocytes, adipocytes were pretreated with either 
1 µM ExperiorTM or 10 µM propranolol for 30 min before adding dobutamine or salbutamol. 
Propranolol was used as positive control. Following pre-treatment with either ExperiorTM or 
propranolol, propranolol reduced glycerol release compared to dobutamine alone (P < 0.05) in s.c 
adipocytes (Figure 18b). ExperiorTM had no effect on glycerol release. There was also not a 
significant effect with ExperiorTM or propranolol with salbutamol treatment (Figure 18c). Neither 
ExperiorTM nor propranolol treatments exhibited antagonistic effects on lipolysis for dobutamine 
or salbutamol treatments in i.m. adipocytes (Figures 19b and 19c). The release of NEFA release 
was markedly decreased by dobutamine treatment in both s.c. and i.m adipocytes (P < 0.05) 
(Figures 18d and 19d). With dobutamine treatment, NEFA release was not reduced by ExperiorTM 
or propranolol in s.c adipocytes (Figure 18e). Overall NEFA results indicated that either ß-AA 
alone or combination did not affect NEFA release for 6 h incubations in either s.c. or i.m. 
adipocytes (Figures 18 and Figure 19). 
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 Based on these data, HSL activity was measured using the ratio of phospho-HSL to total 
HSL using western blots. We successfully detected both phospho-HSL and HSL in s.c. and i.m. 
adipocytes (Figure 20). The activity of HSL did not differ (P > 0.05) between treatments in s.c. 
and i.m. adipocytes. 
 
Figure 18. Glycerol and NEFA release in differentiated s.c. adipocytes in response to 
dobutamine, salbutamol, and ExperiorTM.  At d 14 of differentiation, s.c. adipocytes were 
starved for 2 h in DMEM/F12 containing 0.5% BSA, 0.5 mM IBMX, and 1% antibiotic-
antimycotic at 37°C. Following starvation, cells were pre-stimulated in the presence or absence 
of either 1 µM ExperiorTM or 10 µM propranolol for 30 min. After 30 min, the cells were 
stimulated with 10 µM dobutamine, 10 µM salbutamol or 1 µM ExperiorTM for 6 h. (a-c) 
Glycerol release in the presence or absence of ExperiorTM or propranolol. (d-f) NEFA release in 
the presence or absence of ExperiorTM or propranolol. Data are expressed as means ± SEM (n = 
3). *P < 0.05, **P < 0.01. C, basal; E, ExperiorTM; D, dobutamine; S, salbutamol; P, 
propranolol; DE, dobutamine plus pre-treated with ExperiorTM; DP, dobutamine plus pre-treated 
with propranolol; SE, salbutamol plus pre-treated with ExperiorTM; SP, salbutamol plus pre-




Figure 19. Glycerol and NEFA release in differentiated i.m. adipocytes in response to 
dobutamine, salbutamol, and ExperiorTM. At d 14 of differentiation, i.m. adipocytes were 
starved for 2 h in DMEM/F12 containing 0.5% BSA, 0.5 mM IBMX, and 1% antibiotic-
antimycotic at 37°C. Following starvation, cells were pre-stimulated in the presence or absence of 
either 1 µM ExperiorTM or 10 µM propranolol for 30 min. After 30 min, the cells were stimulated 
with 10 µM dobutamine, 10 µM salbutamol or 1 µM ExperiorTM for 6 h. (a-c) Glycerol release in 
the presence or absence of ExperiorTM or propranolol. (d-f) NEFA release in the presence or 
absence of ExperiorTM or propranolol. Data are expressed as means ± SEM (n = 3). **P < 0.01. C, 
basal; E, ExperiorTM; D, dobutamine; S, salbutamol; P, propranolol; DE, dobutamine plus pre-
treated with ExperiorTM; DP, dobutamine plus pre-treated with propranolol; SE, salbutamol plus 




Figure 20. The ratio HSL Ser563 phosphorylation to total HSL in differentiated s.c. and i.m. 
adipocytes.  Data are expressed as means ± SEM (n = 3). C, basal; E, ExperiorTM; D, dobutamine; 
S, salbutamol; P, propranolol; DE, dobutamine plus pre-treated with ExperiorTM; DP, dobutamine 
plus pre-treated with propranolol; SE, salbutamol plus pre-treated with ExperiorTM; SP, salbutamol 
plus pre-treated with propranolol. 
 
Gene expression associated with lipolysis and lipogenesis by ß-AA and ExperiorTM  
Gene expressions associated with lipolysis and lipogenesis were measured following the 
treatment of ß-agonists and ExperiorTM. At d 14 of differentiation, adipocytes were treated with 10 
µM dobutamine, 10 µM salbutamol, 1 µM ExperiorTM, dobutamine plus ExperiorTM, and 
salbutamol plus ExperiorTM for 3 d in DMEM/F12 containing 2% FBS, and 1% antibiotic-
antimyotic at 37℃. The mRNA levels associated with lipolysis (adipose triglyceride lipase 
(ATGL), hormone-sensitive lipase (HSL), monoacylglycerol lipase (MGLL), perilipin 1 (PLIN1), 
and abhydrolase domain containing 5 (ABHD5)) were measured by RT-qPCR (Figures 21a and 
21b). The expression of HSL was increased by salbutamol, dobutamine plus ExperiorTM, and 
salbutamol plus ExperiorTM compared to control (basal expression) in s.c. adipocytes (P < 0.05). 
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The expression of PLIN1 was upregulated by dobutamine, salbutamol, dobutamine plus 
ExperiorTM, salbutamol plus ExperiorTM in differentiated s.c. adipocytes (P < 0.05). However, 
expression of ATGL, MGLL, and ABHD5 were not affected by ß-AA and ß-AA plus ExperiorTM 
in s.c. adipocytes (Figure 21a). Expression of ATGL was depressed by salbutamol plus ExperiorTM 
as compared to control (P < 0.05) in differentiated i.m. adipocytes. Expression of HSL was 
increased by dobutamine and dobutamine plus ExperiorTM in i.m. adipocytes (P < 0.05). There 
were no differences in MGLL, PLIN1, or ABDH5 gene expression by these treatments in i.m. 
adipocytes (Figure 21b). 
We also measured the expression of genes associated with lipid synthesis and adipocyte 
differentiation: fatty acid-binding protein 4 (FABP4), fatty acid synthase (FASN), and PPAR 
(Figures 21c and 21d). The expression of FABP4 was increased by salbutamol plus ExperiorTM as 
compared to control differentiated s.c. adipocytes (P < 0.05) (Figure 21c). The gene expression of 
FASN and PPAR  were not altered by ß-AA or ß-AA plus ExperiorTM in s.c. adipocytes. There 
were no differences in FABP4, FASN, or PPAR gene expression with any the treatments in i.m. 





Figure 21. Gene expression associated with lipolysis and lipogenesis after 3 d treatment with 
ß-adrenergic agonists and ExperiorTM in differentiated s.c. (a and c) and i.m. (b and d) 
adipocytes. Data are expressed as means ± SEM (n = 3). abcMeans within each treatment sharing 
common superscripts are not different (P < 0.05). C, basal; E, ExperiorTM; D, dobutamine; S, 
salbutamol; P, propranolol; DE, dobutamine plus pre-treated with ExperiorTM; DP, dobutamine 
plus pre-treated with propranolol; SE, salbutamol plus pre-treated with ExperiorTM; SP, salbutamol 
plus pre-treated with propranolol; ATGL, adipose triglyceride lipase; HSL, hormone-sensitive 
lipase; MGLL, monoacylglycerol lipase; PLIN1, perilipin-1; ABHD5, abhydrolase domain 
containing-5; FABP4, fatty acid-binding protein-4; FASN, fatty acid synthase; PPAR, 




Expression of ADRB genes after prolonged exposure of ß-AA and ExperiorTM  
Prolonged stimulation of ß-AA to ß-AR triggers a rapid attenuation of receptor 
responsiveness, known as desensitization.  In response to chronic agonist over-exposure, down-
regulation of the cellular receptors occurs (Ferguson, 2001; Johnson, 2006). Thus, we 
hypothesized that ADRB gene expression would be decreased by ß-AA treatments. The mRNA 
levels of ADRB, ß-adrenergic receptor kinase (BARK) and ß-arrestins (ABBR) were measured 
after chronic exposure of ß-AA and ExperiorTM for 3 d in s.c. and i.m. adipocytes. Subcutaneous 
and i.m. adipocytes exhibited different responses to ß-AA (Figure 22). The expression of ADRB 
was not affected by either ß-AA or ß-AA plus ExperiorTM in in differentiated s.c. adipocytes 
(Figure 22). In contrast, the mRNA levels of ADRB2 were down-regulated by all treatments except 
dobutamine alone in differentiated i.m. adipocytes (P = 0.07). The expression of ADRB3 was 
decreased by all treatments expect salbutamol plus ExperiorTM (Figure 22b). The expression of 
BARK1, BARK2, ARRB1, and ARRB2 was not altered by ß-AA and   ß-AA plus ExperiorTM in both 




Figure 22. Relative mRNA expression of ADRB and gene associated with receptor-
desensitization after 3 d treatment with ß-adrenergic agonists and ExperiorTM in 
differentiated s.c. (a and c) and i.m. (b and d) adipocytes. Data are expressed as means ± SEM 
(n = 3). abMeans within each treatment sharing common superscripts are not different (P < 0.05). 
C, basal; E, ExperiorTM; D, dobutamine; S, salbutamol; P, propranolol; DE, dobutamine plus pre-
treated with ExperiorTM; DP, dobutamine plus pre-treated with propranolol; SE, salbutamol plus 
pre-treated with ExperiorTM; SP, salbutamol plus pre-treated with propranolol; BARK1, ß-
adrenergic receptor kinase-1; BARK2, ß-adrenergic receptor kinase-2; ABBR1, ß-arrestin-1; 
ABBR2, ß-arrestin -2.   
 
Discussion 
This study was designed to examine the effects of a novel ß-AR ligand ExperiorTM on ß1-
and ß2-AR. Also, for the first time we have demonstrated the relative importance of ß1-AR and ß2-
AR in the AC/ PKA/HSL cascade in s.c. and i.m. adipocytes. The current study demonstrated that 
s.c. and i.m. adipocytes have physiologically different responses to ß-AR stimulation by ß-AA. 
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Adenylyl cyclase was highly stimulated by dobutamine (a ß1-AA) and somewhat activated by 
salbutamol (a ß2-AA), but was not affected by Eexperior
TM in s.c. adipocytes. The data for PKA 
activity and glycerol release were similar to results for AC activation in s.c adipocytes. In contrast, 
these ß-AA were not effective in the activation of AC and concomitant PKA activation or in 
glycerol release in i.m. adipocytes. ExperiorTM significantly antagonized the effects of dobutamine 
and salbutamol with in turn suppressed the activations of AC and PKA in s.c. adipocytes. The 
antagonistic efficacy of ExperiorTM was equivalent the effects propranolol, which antagonized the 
stimulation of ß1-AR and ß2-AR in s.c. adipocytes, even though the concentration of Experior
TM 
was 10-fold lower (1 µM) than that of propranolol (10 µM), indicating that ExperiorTM is a 
powerful antagonist of ß-AR.  
During the differentiation of adipocytes, the expression of ß-AR is especially important, 
because catecholamine sensitivity to ß-AR plays a central role in the mechanism for the regulation 
of the transmembrane signaling system that controls energy balance and thermogenesis (Collins, 
2011; Cypess et al., 2015). Adipocytes acquire their responsiveness to catecholamine during 
differentiation (Lai et al., 1982; Feve et al., 1990). Augmentation of ß-AR numbers is paralleled 
by increased levels of ß-AR mRNA because development of catecholamine sensitivity results from 
de novo ß-AR biosynthesis (Feve et al., 1990). There are several reports that changes in ß-AR 
numbers can be also exerted by the action of glucocorticoids like dexamethasone during murine 
3T3 adipocyte differentiation (Lai et al., 1982; Nakada et al., 1987; Feve et al., 1990; Guest et al., 
1990). Upon differentiation, ß1-AR and ß3-AR expression was totally depressed, but ß2-AR 
expression was up-regulated by dexamethasone. Furthermore, in fully mature adipocytes, ß2-AR 
expression was increased, but ß1-AR and ß3-AR expression remained depressed. In contrast, ß2-
AR mRNA expression was not changed upon induction by dexamethasone in bovine skeletal 
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muscle cells (Bridge et al., 1998). In rat C6 glioma cells, ß2-AR mRNA was increased, but there 
was no alteration in ß1-AR mRNA levels after exposure to dexamethasone (Zhong and Minneman, 
1993). Glucocorticoid treatment increased ß1-AR mRNA levels in preterm piglet hearts (Kim et 
al., 2014). Our current study demonstrated that all ß-AR mRNA levels increased during 
differentiation of s.c. adipocytes without a depression of ß1-AR mRNA, even though the cells were 
exposed to dexamethasone during differentiation. These observations illustrate that 
dexamethasone may differently act among species, and other mechanism, including modifying 
membrane composition and the coupling properties of cellular G-proteins, and post-transcriptional 
modifications of ß-AR may be involved in increasing ß-AR numbers during differentiation of 
bovine adipocytes (Lai et al., 1981; Gierschik et al., 1986; Benovic et al., 1987; Storch et al., 1989).  
The current study tested the viability of s.c. preadipocytes after exposure to dobutamine, 
salbutamol, and ExperiorTM in different doses and for different time points using CCK-8 kit. 
Subcutaneous preadipocytes responded differently to individual ß-AA treatments, especially at 
high concentrations (10 µM and 100 µM). Dobutamine highly promoted the proliferation of the 
cells at 10 µM and 100 µM, salbutamol did not induce proliferation at any concentration, and 
ExperiorTM showed toxicity 10 µM and 100 µM after 1 h incubation. In addition, prolonged 
exposures (6 h) to salbutamol significantly induced proliferation. The CCK-8 kit is an enzyme 
based-method that measures mitochondrial dehydrogenase activity. Dobutamine plays an 
important role in mitochondrial bioenergetic function by enhancing the efficiency of mitochondrial 
respiration and by regulating mitochondrial activity in response to increases in energy demands 
(Mukae et al., 1997; Porta et al., 2006; Radhakrishnan et al., 2013). The data of the current study 
suggest the possibility that high concentrations of dobutamine may promote stimulation of 
mitochondrial dehydrogenase in bovine preadipocytes. These results indicate that the chronic ß1-
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AA and ß -AA exposures potentially stimulates proliferation of s.c. adipocytes via stimulation of 
ß-AR.  
Dobutamine strongly activated AC activity in differentiated adipocytes, whereas 
salbutamol did not affect AC activity. Similar results were obtained for PKA activity and glycerol 
release in s.c adipocytes. Although both dobutamine and salbutamol are potent ß-AA, they may 
modulate different levels of receptor occupation because very small populations of receptors could 
produce large responses (Kenakin, 1995). Therefore, data of the present study suggest that agonist-
receptor efficacy between ß1-AR and dobutamine may be much stronger than agonist-receptor 
efficacy between ß2-AR and salbutamol in bovine s.c. adipocytes differentiated in culture, which 
would cause greater Gs coupling with AC via the ß1-AR.  
Pre-treatment with ExperiorTM strongly antagonized individual ß1-AR and ß2-AR and 
subsequently depressed the AC and PKA activity stimulated by dobutamine and salbutamol in s.c. 
adipocytes differentiated in culture. The antagonism of the ß2-AR with Experior
TM was also 
observed in i.m. adipocytes.  Although, ExperiorTM significantly suppressed PKA activity, neither 
glycerol nor NEFA release was influenced in s.c. and i.m adipocytes by ExperiorTM. In addition, 
ExperiorTM had no effect on gene regulation such as ADRB, or genes associated with lipid filing 
and lipolysis. Hence, ExperiorTM may function only in modulating ß-AR activation. The 
antagonistic efficacy of ExperiorTM was similar to propranolol, a non-selective ß-AR antagonist. 
These findings support the concept that ExperiorTM works as an antagonist for ß1-AR or ß2-AR in 
bovine adipocytes. According to Freddolino et al. (2004) the agonists epinephrine, norepinephrine, 
salbutamol, and isoproterenol strongly bind to Ser-203, Ser-204, and Ser-207 at transmembrane 5 
(TM5). Antagonists such as propranolol and butoxamine bind to Ser-203 but not to Ser-207 at 
TM5, which leads to more flexible binding to TM5 not to transit to the activated state (Freddolino 
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et al., 2004). This suggests the possibility that ExperiorTM may have similar binding properties as 
propranolol in bovine ß1-AR or ß2-AR. Further, the activities of antagonists can be completely 
dependent upon the tissues or cell types (Kenakin, 1987). This also would explain why both 
ExperiorTM and propranolol strongly blocked individual both ß1-AR and ß2-AR in s.c. 
differentiated adipocytes, but only antagonized ß2-AR in i.m. adipocytes. 
An increased catabolism and a decreased anabolism of lipid in the adipocytes by ß-AR 
stimulation would decrease hypertrophy of the adipocyte through a consequent decrease in 
formation of lipid droplets (Smith, 1987). In lipid catabolism, ATGL, HSL and MGL are the most 
important lipases. Upon ß-AR stimulation, PKA phosphorylates PLIN on the surface of lipid 
droplets, leading to ABHD5 release, which then binds and activates ATGL to hydrolyze 
triglycerides. PKA also phosphorylates HSL in the cytoplasm, after which HSL translocates to 
lipid droplets where it binds to PLIN to hydrolyzes diacylglycerides, and MGL hydrolyzes 
monoglycerides (Zimmermann et al., 2009; Zechner et al., 2012). Thus, ATGL activity is 
indirectly induced by PKA stimulation by ß-AR whereas HSL activity is induced by direct HSL 
phosphorylation.  Our current study examined the expression of these five genes after exposure to 
dobutamine, salbutamol, and ExperiorTM for 3 d. Salbutamol and dobutamine increased HSL gene 
expression in s.c. adipocytes and i.m. adipocytes, respectively, and both dobutamine and 
salbutamol increased PLIN gene expression in s.c adipocytes. Taken together, the data suggest that 
the expression of HSL and PLIN contributes to an increase in lipolysis by increasing these lipolytic 
proteins. Because we only measured mRNA abundance, we can only speculate the importance of 
the role of the ß-AR in the current study. These contributions of individual ß-AR likely involve 
multiple factors such as ß-AR function, transcription factors, and the rate of mRNA decay. 
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In conclusion, we have demonstrated for the first time the pattern of ADRB expression in 
i.m. adipocytes. In spite of expressing all three ADRB subtypes, i.m. adipocytes were refractory 
of specific ß-AA, suggesting that treatment of cattle with commercial ß-AA would not directly 
affect lipid filling in i.m. adipose tissue. This study also demonstrated different physiological 
responses of ß-AR subtypes to selective ß1-AA, ß2-AA, and Experior
TM in differentiated s.c. and 
i.m. adipocytes. Even though the ß2-AR is considered the predominant ß-AR subtype in the adipose 
tissue, the three ß-AR mRNA levels in differentiated adipocytes were not different. Dobutamine, 
a selective ß1-AA, significantly stimulated AC/PKA activity and lipolysis in s.c. adipocytes and 
was more potent than salbutamol, a selective ß2-AA. These findings imply that the efficacious 
ligands for regulating adipose tissue accretion could effectively signal through both the ß1-AR and 
ß2-AR in bovine species. The antagonistic efficacy of Experior
TM was similar that of propranolol 
even the concentration of propranolol was 10-fold higher than that of ExperiorTM. Our findings 
also indicate that ExperiorTM may function as a potent antagonist for both ß1-AR and ß2-AR in 





The objectives of this research were to investigate lipid desaturation by ectopically 
expressed pSCD1 in non-adipocytes and to investigate the extent of lipolysis mediated by ß-AR 
subtypes through various kinds of selective ß-AR agonists ex vivo and in vitro.  
The first major point of this research was to successfully generate inducible lentiviral 
expression vectors to overexpression or knock-down of pSCD1 and to validate its stably expression 
and functional catalytic activity in SK6-I-pSCD1 cells through RT-qPCR, western blot and fatty 
acid analysis. SK6-I-pSCD1 cells incubated with palmitic acid increased the synthesis of 
palmitoleic acid nearly 4-fold, indicating that the pSCD1- transduced cells successfully can induce 
the ∆9 desaturation of palmitic acid to palmitoleic acid. Based on these results, we confirmed that 
pSCD1 expression was ectopically controlled using inducible lentiviral system. Further, it implies 
that the lentiviral constructs utilized in this study can be utilized to generate transgenic pigs or 
other cell lines to enhance our understanding of the contribution of fatty acid desaturation and 
concomitant to lipogenesis to the promotion of disease states such as obesity and metabolic 
disease.  
 The second major point of this research was to characterize ß-AR subtypes in bovine s.c. 
and i.m.  adipose tissues with the use of selective ß-,  ß- and ß-AR agonists. This study 
documented the distribution of ADRB in bovine s.c. and i.m. adipose tissues from growing cattle. 
In addition, the distribution of ADRB in i.m. adipose tissue was demonstrated for the first time. 
The interesting findings of this study were that ADRB1and ADRB3 mRNA showed similar levels 
of expression in both s.c. and i.m. adipose tissues; ADRB3 in cattle had been believed to be 
expressed only in BAT.  
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We also demonstrated that s.c. and i.m. adipose tissues have physiologically different 
responses to ß-AR agonists. ß1/2-AR agonists including isoproterenol, RH, and ZH, increased 
lipolysis in s.c. adipose tissue but were not effective in i.m. adipose tissue, even though cAMP 
production was greater in i.m. adipose tissue than in s.c. adipose tissue for all experiments. We 
speculated the reasons that the levels of gene expression of ß-AR were much lower in i.m. adipose 
tissue than that of s.c. adipose tissue, which indicated a small amount of ß-AR populations in i.m. 
adipose tissue. Therefore, ß-AR would be easily occupied even at very low concentrations of ß-
AR agonist in i.m. adipose, which would lead to low efficacy to signal downstream inducing 
lipolysis.   
The ß3-AR predominantly mediates the lipolytic response through selective ß3-AR agonists 
such as CL-316243 and BRL-37344 in rodents, rabbits, and dogs, but there is no evidence for the 
existence of a functional ß3-AR in bovine adipose tissue from physiologically mature cattle. Our 
study examined the presence of a functional ß3-AR in response to BRL-37344, and Experior
TM 
revealed that neither 3-AR agonists stimulated cAMP production or NEFA release from s.c. and 
i.m. adipose tissues. The data suggested that ß3-AR may not be functional in bovine adipose 
tissue, regardless of the fact that the tissue distribution of ß3-AR in cattle was similar ß1-AR in 
bovine adipose tissue.  
The final major objective of this research was to investigate antagonistic effects on ß-AR 
mediated by ExperiorTM in primary bovine s.c. and i.m. adipocytes. The results of this study 
demonstrated that ExperiorTM depressed cAMP production in the presence of either propranolol or 
L-748,337 in s.c. adipose tissue. Further, ExperiorTM strongly depressed the cAMP accumulation 
stimulated by dobutamine and salbutamol in a dose-dependent manner. These findings suggested 
that ExperiorTM may function as a competitive antagonist for ß1-AR or ß2-AR in bovine adipose 
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tissue. Thus, we further investigated antagonistic effects on ß-AR/AC/PKA/HSL signaling cascade 
through ExperiorTM in bovine s.c and i.m. mature adipocytes. The data demonstrated that 
ExperiorTM strongly repressed the ß-AR/AC/PKA signaling cascades in s.c and i.m adipocytes. 
However, neither glycerol and NEFA release nor HSL activity was not influenced by ExperiorTM 
in s.c. and i.m adipocytes. In addition, ExperiorTM did not affect gene expression such as ADRB 
and lipogenesis- and lipolysis- associated gene expression. Hence, these results suggested that 
ExperiorTM may function by only modulating receptor activation. The antagonistic efficacy of 
ExperiorTM was similar to that of propranolol, even though the concentration of ExperiorTM was 
10-fold lower than that of propranolol in our experiments. Through these finding, we confirmed 
again that ExperiorTM acts as an antagonist for ß1-AR or ß2-AR in bovine adipose tissue. 
 Taken together, this dissertation has suggested the opportunity not only to develop a non-
rodent biomedical model of obesity and metabolic disease but also to produce beef products with 
heart healthy characteristics, which can contribute to human health and economic profits to the 
beef cattle industry. It has also contributed to the understanding of functionality of ß-AR subtypes 
in adipose tissue during cattle growth and maturity. This research also demonstrated different 
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